

Experimental Physiology

<https://ep.msubmit.net>

**EP-RP-2019-088350R2**

**Title:** The 2018 Global Research Expedition on Altitude-related Chronic Health (REACH) to Cerro de Pasco, Peru: An Experimental Overview

**Authors:** Michael M Tymko

Ryan L Hoiland

Joshua C Tremblay

Mike Stembridge

Tony Dawkins

Geoff B Coombs

Alex Patrician

Connor A Howe

Travis Dylan Gibbons

Jonathan P Moore

Lydia Louise Simpson

Craig D Steinback

Victoria L Meah

Benjamin S Stacey

Damian Miles Bailey

David B MacLeod

Chris Gasho

James Anholm

Anthony Richard Bain

Justin Stevan Lawley

Francisco Villafuerte

Gustavo Vizcardo-Galindo

Philip N Ainslie

**Disclaimer:** This is a confidential document.

**Author Conflict:** No competing interests declared

**Running Title:** Global REACH High Altitude Expedition to Peru

**Abstract:** In 2016, the international research team - Global Research Expedition on Altitude-related Chronic Health (REACH) - was established and executed a high altitude research expedition to Nepal. The team consists of ~45 students, principal investigators and physicians with the common objective of conducting experiments focused on high altitude adaptation in lowlanders, and highlanders with lifelong exposure to high altitude. In 2018, Global REACH traveled to Peru where we performed a series of experiments in the Andean highlanders. The experimental objectives, organization and characteristics, and key cohort data from Global REACH's latest research expedition are outlined herein.

Herein, fifteen major studies are described that aimed to elucidate the physiological differences in high altitude acclimatization between lowlanders (n=30) and Andean born highlanders with (n=22) and without (n=45) Excessive Erythrocytosis (EE). After baseline testing in Kelowna, BC, Canada (344m), Global REACH travelled to Lima, Peru (~80 m), and then ascended by automobile to Cerro de Pasco, Peru (~4300m) where experiments were conducted over 25 days. The core studies focused on elucidating the mechanism(s) governing cerebral and peripheral vascular function, cardiopulmonary regulation, exercise performance, and autonomic control. Despite encountering serious logistical challenges, each of the proposed studies were completed at both sea level and high altitude amounting to ~780 study sessions and >3000 hrs of experimental testing. Participant demographics and data related to acid-base balance and exercise capacity are presented. The collective findings will contribute to our understanding of how lowlanders and Andean highlanders have adapted under high altitude stress.

**New Findings:** What is the central question of this study? Herein, a methodological overview of our research team's latest high altitude research expedition to Peru is provided. What is the main finding and its importance? The experimental objectives, expedition organization, measurements, and key cohort data are discussed. The select data presented in the current manuscript demonstrated some of the hematological differences between lowlanders and Andeans with and without excessive erythrocytosis, and that relative exercise capacity was similar between study groups at high altitude. The forthcoming findings from our research expedition will contribute to our understanding of lowlander acclimatization and highlander adaptation.

**Dual Publication:** No

**Disclaimer:** This is a confidential document.

**Funding:** Canada Research Chair: Philip N Ainslie, F16-02798; Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (Conseil de Recherches en Sciences Naturelles et en Génie du Canada): Philip N Ainslie, F18-00605; Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (Conseil de Recherches en Sciences Naturelles et en Génie du Canada): Michael M Tymko, Doctoral Grant

1 **Journal:** *Experimental Physiology*  
2  
3 **Title:** The 2018 Global Research Expedition on Altitude-related Chronic Health  
4 (REACH) to Cerro de Pasco, Peru: An Experimental Overview  
5  
6 **Authors:** <sup>1,6</sup>Michael M. Tymko, <sup>1</sup>Ryan L. Hoiland, <sup>2</sup>Joshua C. Tremblay, <sup>3</sup>Mike  
7 Stembridge, <sup>3</sup>Tony Dawkins, <sup>1</sup>Geoff B. Coombs, <sup>1</sup>Alexander Patrician, <sup>1</sup>Connor  
8 A. Howe, <sup>4</sup>Travis D. Gibbons, <sup>5</sup>Jonathan P. Moore, <sup>5</sup>Lydia L. Simpson, <sup>6</sup>Craig D.  
9 Steinback, <sup>6</sup>Victoria L. Meah, <sup>7</sup>Benjamin S. Stacey, <sup>7</sup>Damian M. Bailey, <sup>8</sup>David  
10 MacLeod, <sup>9</sup>Christopher Gasho, <sup>9</sup>James Anholm, <sup>10,11</sup>Anthony Bain; <sup>12</sup>Justin S.  
11 Lawley, <sup>13</sup>Francisco Villafuerte, <sup>13</sup>Gustavo Vizcardo, <sup>1</sup>Philip N. Ainslie.  
12  
13 **Affiliations:** <sup>1</sup>Centre for Heart, Lung and Vascular Health, School of Health and Exercise  
14 Sciences, University of British Columbia – Okanagan, Kelowna, British  
15 Columbia, Canada.  
16 <sup>2</sup>Cardiovascular Stress Response Laboratory, School of Kinesiology and Health  
17 Studies, Queen’s University, Kingston, Ontario  
18 <sup>3</sup>Cardiff Centre for Exercise and Health, Cardiff School of Sport and Health  
19 Sciences, Cardiff Metropolitan University, Cardiff  
20 <sup>4</sup>School of Physical Education, Sport and Exercise Sciences, University of Otago,  
21 Dunedin, New Zealand.  
22 <sup>5</sup>Bangor University, Wales, UK  
23 <sup>6</sup>Faculty of Physical Education and Recreation, University of Alberta, Edmonton,  
24 Canada  
25 <sup>7</sup>Neurovascular Research Laboratory, Faculty of Life Sciences and Education,  
26 University of South Wales, Glamorgan, UK  
27 <sup>8</sup>Human Pharmacology & Physiology Lab, Duke University Medical Center,  
28 Durham, NC, USA.  
29 <sup>9</sup>Department of Medicine, Division of Pulmonary and Critical Care, Loma Linda  
30 University School of Medicine, Loma  
31 <sup>10</sup>University of Colorado, Boulder, Colorado  
32 <sup>11</sup>University of Windsor, Ontario, Canada  
33 <sup>12</sup>University of Innsbruck, Innsbruck, Austria  
34 <sup>13</sup>Universidad Peruana Cayetano Heredia, Lima, Peru  
35  
36 **Correspondance:** Michael M. Tymko, PhD.  
37 Centre for Heart, Lung and Vascular Health  
38 School of Health and Exercise Sciences  
39 Faculty of Health and Social Development  
40 University of British Columbia  
41 3333 University Way, Kelowna, BC, V1V 1V7  
42 Telephone: 1-250-470-8608  
43 Email: mike.tymko@alumni.ubc.ca  
44 **Word Count:** 8157  
45 **Number of Figures:** 3  
46 **Number of Tables:** 4

47 **What is the central question of this study?**

48

49 Herein, a methodological overview of our research team's (Global REACH) latest high altitude  
50 research expedition to Peru is provided.

51

52 **What is the main finding and its importance?**

53

54 The experimental objectives, expedition organization, measurements, and key cohort data are  
55 discussed. The select data presented in the current manuscript demonstrate the hematological  
56 differences between lowlanders and Andeans with and without excessive erythrocytosis, and that  
57 exercise capacity was similar between study groups at high altitude. The forthcoming findings  
58 from our research expedition will contribute to our understanding of lowlander and indigenous  
59 highlander high altitude adaptation.

60

61

62 **Abstract**

63

64 In 2016, the international research team - Global Research Expedition on Altitude-related  
65 Chronic Health (REACH) - was established and executed a high altitude research expedition to  
66 Nepal. The team consists of ~45 students, principal investigators and physicians with the  
67 common objective of conducting experiments focused on high altitude adaptation in lowlanders,  
68 and highlanders with lifelong exposure to high altitude. In 2018, Global REACH traveled to Peru  
69 where we performed a series of experiments in the Andean highlanders. The experimental  
70 objectives, organization and characteristics, and key cohort data from Global REACH's latest  
71 research expedition are outlined herein. Herein, fifteen major studies are described that aimed to  
72 elucidate the physiological differences in high altitude acclimatization between lowlanders  
73 (n=30) and Andean born highlanders with (n=22) and without (n=45) Excessive Erythrocytosis  
74 (EE). After baseline testing in Kelowna, BC, Canada (344m), Global REACH travelled to Lima,  
75 Peru (~80 m), and then ascended by automobile to Cerro de Pasco, Peru (~4300m) where  
76 experiments were conducted over 25 days. The core studies focused on elucidating the  
77 mechanism(s) governing cerebral and peripheral vascular function, cardiopulmonary regulation,  
78 exercise performance, and autonomic control. Despite encountering serious logistical challenges,  
79 each of the proposed studies were completed at both sea level and high altitude amounting to  
80 ~780 study sessions and >3000 hrs of experimental testing. Participant demographics and data  
81 related to acid-base balance and exercise capacity are presented. The collective findings will  
82 contribute to our understanding of how lowlanders and Andean highlanders have adapted under  
83 high altitude stress.

84

85 **Key words:** High-altitude, hypobaric hypoxia, Andean highlanders, Global REACH

86

87 **Introduction**

88 Indigenous populations of the high plateaux of Tibet (Sherpa), Peru (Quechua), and Ethiopia  
89 (Amhara and Oromo) have developed distinct physiological adaptations to thrive in their  
90 respective hypoxic environments (Beall, 2006). Although there is considerable debate on when  
91 these plateaux were occupied, the consensus is that the Old World plateaux have been inhabited  
92 longer (Ethiopian ~50,000 to ~70,000 years; Tibetan ~30,000 to ~40,000 years), compared to the  
93 Altiplano in the New World (Peruvian ~7,000 to ~10,000 years) (Aldenderfer, 2003, 2008;  
94 Alkorta-Aranburu et al., 2012; Beall, 2006, 2007a; Beall et al., 2002; Haas et al., 2017;  
95 Pleurdeau, 2005; Zhang et al., 2018). The majority of these indigenous populations show  
96 impressive function at high altitude compared to lowlanders – function that arises from  
97 fundamental changes in oxygen delivery and utilization. The Sherpa typically have lower  
98 hemoglobin concentration compared to other highlanders at similar altitudes such as the Peruvian  
99 Quechuan (Beall, 2006; Gassmann et al., 2019). Some (Gilbert-Kawai, Milledge, Grocott, &  
100 Martin, 2014; Tremblay, Hoiland, et al., 2018), but not all studies (Liu et al., 2016; Wang et al.,  
101 2018), indicate that Sherpa rely on enhanced blood flow and endothelial function to sustain  
102 convective oxygen delivery, and also on cellular metabolic adaptations to utilize oxygen more  
103 efficiently (Horscroft et al., 2017). In contrast, the Quechua highlanders exhibit increased  
104 hemoglobin concentration in response to high altitude exposure, but they are more prone to  
105 developing chronic mountain sickness, of which excessive erythrocytosis (EE) is one  
106 characteristic feature (being defined as a hemoglobin concentration of  $\geq 19$  g dl<sup>-1</sup> and  $\geq 21$  g dl<sup>-1</sup>  
107 in females and males, respectively). Although the pathological origins of hypoxia-induced EE  
108 are still not fully understood and may be secondary to existing disease (Villafuerte & Corante,  
109 2016), or due to genetic drift (Bermudez et al., 2019; A. M. Cole, Petousi, Cavalleri, & Robbins,

110 2014; Hsieh et al., 2016; Zhou et al., 2013), EE leads to elevated blood viscosity (which  
111 increases the resistance to blood flow through the vasculature), and elevated systemic oxidative-  
112 inflammatory-nitrosative stress (Bailey et al., 2018; Bailey et al., 2013). Less is known about the  
113 adaptations (or maladaptations) of Ethiopian highlanders (Amhara and Oromo populations) from  
114 the Simien and Bale mountains, respectively. The Amhara, but not Oromo highlanders, have  
115 hemoglobin concentrations similar to lowlanders, yet higher than expected arterial oxygen  
116 saturation, potentially due to an increased affinity of hemoglobin for oxygen (Beall, 2006; Beall  
117 et al., 2002), which can be altered by temperature, pH, PCO<sub>2</sub>, and 2,3-bisphosphoglyceric acid.  
118 Conceivably, the Sherpa, Quechua, and Amhara phenotypes represent distinct evolutionarily-  
119 driven strategies that permit survival and performance at high altitude (Beall, 2006, 2007b; Beall  
120 et al., 2002).

121         In 2016, our international research team, Global Research Expedition on Altitude-related  
122 Chronic Health (REACH) was formed with the research objective to execute a series of  
123 experiments on the Tibetan, Peruvian, and Ethiopian highlanders. High altitude physiology  
124 research offers valuable insight on the mechanistic adaptation to hypoxia, which is translatable to  
125 a myriad of clinical diseases characterized by hypoxemia (Levett et al., 2010). The timing of this  
126 research is urgent, as migration and modernization are rapidly changing traditional ways of life  
127 and altitude exposure of high altitude dwellers (Beall, 2013). In October 2016, our research team  
128 successfully conducted a series of experiments in lowlanders and Sherpa at the Ev-K2 Pyramid  
129 International Laboratory/Observatory near Mt. Everest basecamp (5050m) (Willie et al., 2018),  
130 and in July of 2018, Global REACH traveled to Cerro de Pasco, Peru (4300m) to conduct a  
131 similar series of experiments in the Quechua highlanders with and without EE. An estimated 5-  
132 10% of high altitude dwellers are at risk of developing EE (Leon-Velarde et al., 2005; Villafuerte



133 & Corante, 2016), which is a public health concern primarily in the Andes, but also in  
134 Kyrgyzstan, Northern India, and among migrants to high altitude in Tibet and the United States  
135 (Pei et al., 2012; Penaloza & Arias-Stella, 2007; Sahota & Panwar, 2013). Among the highest  
136 reported prevalence is in the mining city of Cerro de Pasco, Peru, where 15% of men aged 30-39,  
137 and 34% aged 60-69 present with EE (Monge, Leon-Velarde, & Arregui, 1989). Additionally, a  
138 recent meta-analysis demonstrated that there are differences in hemoglobin concentration  
139 between highlander populations (Gassmann et al., 2019), and in agreement with previous reports  
140 (Beall, 2006, 2007b; Beall et al., 2002), this meta-analysis indicated that Andean highlanders  
141 have higher hemoglobin concentration and hematocrit compared to other highlander populations  
142 (e.g. Sherpa and Ethiopians).

143         Similarly to the overview manuscript written based on our team's research expedition to  
144 Nepal (Willie et al., 2018), we provide a methodological summary of Global REACH's research  
145 expedition to Cerro de Pasco, the second installment of our team's common research objective to  
146 study and compare the Tibetan, Peruvian, and Ethiopian highlanders. In both expeditions the  
147 core studies focused on elucidating the mechanism(s) governing cerebral and peripheral vascular  
148 function, cardiopulmonary regulation, exercise performance, and autonomic control. The  
149 principal scientific themes, experimental details, and key cohort data of our Peru expedition are  
150 discussed within. The results of the specific studies outlined will be published as separate  
151 manuscripts.

152

153 **Method and Materials**

154 ***Ethical approval.*** In accordance with the *Declaration of Helsinki*, except for registration in a  
155 database, the lowlander and highlander based studies were approved by the UBC Clinical  
156 Research Ethics Board (H17-02687 and H18-01404, respectively), and local Peruvian ethics  
157 committee for the Universidad Peruana Cayetano Heredia (#101686). All lowlander and  
158 highlander study participants provided informed consent (English and Spanish consent forms  
159 were available) after each study was thoroughly explained in their native language. Prior to  
160 voluntary consent, we provided opportunity for questions directly with each study principal  
161 investigator. For each study involving highlanders in Cerro de Pasco, Peru, an official translator  
162 was present for the entire testing duration to ensure proper communication was maintained  
163 between the researchers and participant. All participants were free to withdraw without  
164 justification or penalty from all experiments at any time. Andean participants were monetarily  
165 compensated for their time based on a payment suggested by the Universidad Peruana Cayetano  
166 Heredia research ethics board.

167

168 ***Global REACH.*** Our research team, consisting of 45 students, principal investigators, and  
169 physicians commenced baseline studies in March 2018, and travelled to Cerro de Pasco between  
170 June 26-28<sup>th</sup> 2018, where the majority of the team remained until July 22<sup>nd</sup> 2018 (*refer to figure*  
171 *1*). The leadership for the research expedition originated from the University of British Columbia  
172 - Okanagan (Canada), University of Alberta (Canada), Duke University (United States), Loma  
173 Linda University (United States), University of Innsbruck (Austria), University of Boulder  
174 Colorado (United States), Cardiff Metropolitan University (United Kingdom), University of  
175 Cambridge (United Kingdom), University of South Wales (United Kingdom), and Bangor

176 University (United Kingdom). The research expedition, was aided by the help of local  
177 collaborator, Dr. Francisco Villafuerte, and three graduate students from the Universidad  
178 Peruano Cayetano Heredia, Peru.

179  
180 **Participants.** All Global REACH members were of European descent (two generations self-  
181 reported) and were born and currently living below 1500m. All lowlander participants avoided  
182 visiting high altitude (>1500m) for at least six-months prior to the expedition. Each expedition  
183 study had different sample sizes pooled from the same cohort of participants according to  
184 prospective power calculations (*see below*). Global REACH members were included in up to 11  
185 experiments at either sea level and/or high altitude with adequate recovery between each and  
186 close attention to non-contamination between protocols (e.g. washout following drug infusion).  
187 The Andean highlanders were only tested at high altitude. Andean highlanders were recruited  
188 through an established database compiled in-part by Dr. Villafuerte from the Universidad  
189 Peruana Cayetano Heredia, Lima, Peru. Highlanders were recruited by telephone by one of three  
190 local translators. During a familiarization visit to the high altitude laboratory, a detailed self-  
191 reported family and altitude history was collected from all Andean participants including  
192 altitudes during childhood, in adulthood, and for the 12-months preceding the studies. All  
193 recruited Andean participants (and at least two previous known generations) were born at, and  
194 permanently lived at high altitude (within the Cerro de Pasco region). After providing informed  
195 consent, each recruited Andean participant was requested to fill out a Qinghai CMS  
196 questionnaire (Leon-Velarde et al., 2005). Studies involving both lowlanders and Andean  
197 highlanders attempted to age and sex match participants (i.e. match Andean highlanders to the  
198 already enrolled lowlanders). Prior to any study at either low or high altitude, participants were

199 asked to refrain from exercise and caffeine for a minimum of 12-hours, and were fasted for a  
200 minimum of two-hours. We also obtained an antecubital venous blood sample for the  
201 measurement of hematocrit and hemoglobin. Due to the high number of proposed investigations  
202 that needed to be completed within a short time-frame, six laboratories in Cerro de Pasco ran  
203 simultaneously and typically operated for 12-18 hrs/daily. Study participants were included if  
204 they were between the ages of 18-60 years old without any medical history of cardiovascular,  
205 cerebrovascular, pulmonary, metabolic disease, or history of working in the local mines (e.g.  
206 Lead, Cobalt, and Sulphur mines). However, blood analyses for heavy metals such as Lead and  
207 Cobalt were not performed and are potential cofounders to our data sets. A subset of  
208 premenopausal women aged 18-30 were recruited to investigate potential sex differences within  
209 healthy (i.e. non-EE) Andeans.

210

211 ***Chronic Mountain Sickness.*** . Chronic mountain sickness was determined using the Qinghai  
212 CMS score (Leon-Velarde et al., 2005). A score of zero (i.e. absent), to three (i.e. severe), was  
213 assigned for the following signs and symptoms: breathlessness/palpitations, sleep disturbance,  
214 cyanosis, venodilation, paresthesia, headache, and tinnitus. The sum of the score for each  
215 symptom and EE defines CMS severity as absent (0-5), mild (6-10), moderate (11-14), and  
216 severe ( $\geq 15$ ).

217

218 ***Low and high altitude laboratories.*** Between February-April 2018, baseline studies were  
219 conducted in the Cerebrovascular Physiology Laboratory at the University of British Columbia –  
220 Okanagan (Kelowna, BC, Canada). There, the large laboratory ( $P_B = \sim 730$  mmHg, humidity=  
221  $\sim 30\%$ , laboratory temperature =  $\sim 22^\circ\text{C}$ ) was divided into five separate simultaneous testing

222 areas, and one space was dedicated to blood analysis compliant with standard research  
223 governance guidelines. Global REACH arrived in Cerro de Pasco in late June 2018. The testing  
224 facility associated with the Universidad Peruana Cayetano Heredia in Cerro de Pasco was  
225 expansive ( $P_B = \sim 450$  mmHg, humidity =  $\sim 75\%$ , laboratory temperature =  $\sim 15^\circ\text{C}$ ), being able to  
226 accommodate six complex (i.e., invasive and/or pharmacological) studies running  
227 simultaneously. Electricity was consistent for the majority of expedition; however, on  $\sim 5$  days  
228 we encountered long-term black-outs and power surges. The latter resulted in short-lasting  
229 electrical fires. Therefore, all equipment was equipped with surge protectors, and after the first  
230 local electrical blackout (of several), a large generator served as a back-up power source for the  
231 remainder of our expedition. Another regular issue encountered was water supply shortage. The  
232 laboratory was not accustomed to housing  $\sim 45$  guests at once (excluding Andean participants).  
233 Our team consistently ran out of water for the facility's toilets and sinks, and needed to get the  
234 water reservoir filled 1-2 times per week.

235

236 ***Equipment Logistics.*** Over four metric tonnes of equipment and consumable items (e.g. needles,  
237 syringes, saline), with a value amounting to  $\sim 1.3$  million dollars (USD) were packed in a  
238 combination of pelican cases, duffle bags, suitcases, and waterproof barrels. Back-up equipment  
239 for nearly every research device was packed in case of equipment failure at high altitude. This  
240 equipment travelled as checked-baggage on multiple international flights with each Global  
241 REACH team member. More fragile equipment, such as Duplex ultrasound machines and  
242 laptops, accompanied team members as carry-on luggage. Appropriate documents for legal  
243 importation of all equipment and consumable items were obtained prior to traveling to Peru.  
244 Despite these efforts,  $\sim 15\%$  of our equipment was rejected entry into Peru upon arrival; however,

245 through sustained perseverance by both Global REACH members and our local Peruvian  
246 collaborators, these items were released from Peru customs within ~14 days. In advance, 43 K-  
247 and T-size compressed gas cylinders were purchased (Linde Industrial Gas, Lima, Peru) and  
248 delivered to the high altitude laboratory in Cerro de Pasco. One small compressed gas cylinder of  
249 100% oxygen was acquired as a safety precaution in the event of an emergency evacuation of a  
250 team member (or Andean participant) related to altitude illness – thankfully, no serious adverse  
251 health outcomes were experienced. Several studies required blood and plasma samples to be  
252 flash frozen and stored in liquid nitrogen Dewars prior to transportation back to the  
253 Canada/UK/USA for batch analyses. Liquid nitrogen was sourced locally in Lima, Peru from an  
254 industrial gas supplier (Linde).

255

256 *Ascent profile to Cerro de Pasco.* Global REACH members traveled to Lima, Peru, in June ~2-  
257 7 days prior to departure to Cerro de Pasco. During this time, final equipment organization and  
258 preparations were completed, including the processing of several documents to release the  
259 equipment that remained in Peru customs. Research equipment, personal luggage, and liquid  
260 nitrogen Dewar's were transported by a one-tonne cube truck to Cerro de Pasco (~270 km; ~7-8  
261 hour drive). Global REACH team members, along with local collaborators were transported by  
262 cargo van on three separate days (June 26<sup>th</sup>, 27<sup>th</sup>, and 28<sup>th</sup>). Participants refrained from taking  
263 prophylactic medication against high altitude illness (e.g. Acetazolamide). However, if  
264 participants requested medication to relieve symptoms while at high altitude, or were requested  
265 by our physicians to undergo treatment, it was made available to them and their health and  
266 symptoms were monitored closely. The majority of the Global REACH team spent 3-4 weeks in  
267 Cerro de Pasco completing all studies.

268

## 269 **Commonly Employed Methodologies**

270 *Dynamic end tidal forcing.* Several studies required the precise control of arterial blood gases  
271 for a portion, or for the entire duration of their protocol. To accomplish this, we employed a  
272 portable dynamic end-tidal forcing system (*Airforce*, UBC, Canada) to control the partial  
273 pressure of end-tidal oxygen and carbon dioxide ( $P_{ET}O_2$  and  $P_{ET}CO_2$ , respectively), as a surrogate  
274 for the partial pressure of arterial oxygen and carbon dioxide ( $PaO_2$  and  $PaCO_2$ , respectively)  
275 (Tymko, Ainslie, MacLeod, Willie, & Foster, 2015; Tymko et al., 2016). Our custom-built  
276 system uses independent gas solenoid valves for  $O_2$ ,  $CO_2$ , and  $N_2$  and controls the volume of  
277 each gas being delivered to an inspiratory reservoir through a mixing and humidification  
278 chamber on a breath-by-breath basis. This system has been used previously to effectively control  
279 end-tidal gases during many different physiological stressors, and its use has been validated at  
280 high altitude (Tymko et al., 2015). Although this device works extremely well in participants  
281 with background knowledge in respiratory physiology, extensive training and instruction was  
282 required from our local translators to aid the Andean participants to breathe normally on the  
283 device for specific research studies.

284

285 *Respiratory and cardiovascular measurements.* Nearly all respiratory and cardiovascular  
286 parameters were acquired using an analog-to-digital converter (Powerlab/16SP ML 880;  
287 ADInstruments, Colorado Springs, CO, USA) interfaced with a personal computer.  
288 Commercially available software was used to analyze ventilatory and cardiovascular variables  
289 (LabChart V7.1, ADInstruments, Colorado Springs, CO, USA). Respired gases were sampled at  
290 the mouth and analyzed for  $P_{ET}O_2$  and  $P_{ET}CO_2$  (ML206; ADInstruments, Colorado Springs, CO,

291 USA). During the expedition, two gas analyzers failed due to pump failure and excess  
292 condensation, the latter issue was able to be resolved. Respiratory flow was also measured near  
293 the mouth using a pneumotachograph (HR 800L, HansRudolph, Shawnee, KS, USA) and a  
294 differential pressure amplifier (ML141, ADInstruments, Colorado Springs, CO, USA). One  
295 unexpected problem we encountered due to the high volume of data collection (i.e. >12 hours of  
296 continuous respiratory data collection each day) was excess condensation accumulating in the  
297 pneumotachometers resulting in respiratory “drift” and signal artifact. This issue was resolved by  
298 replacing spirometry filters more frequently (e.g. two per participant), and/or by replacing the  
299 pneumotach. Heart rate was determined from a standard lead II electrocardiogram (ML 132,  
300 ADInstruments, Colorado Springs, CO, USA), and the majority of blood pressure measurements  
301 were conducted on a beat-by-beat basis using finger photoplethysmography (Finometer pro,  
302 Finapres Medical Systems, Netherlands). At times, due to the cold environment, a hot water  
303 bottle was required to elevate and then maintain the participant’s hand temperature prior to  
304 experimentation, in order to obtain a proper blood pressure waveform. Additionally, all studies  
305 recorded manual blood pressure measurements before and throughout experimentation to both  
306 confirm and calibrate the finometer blood pressure waveform.

307

308 ***Transcranial and duplex Doppler ultrasound.*** Several studies required the use of transcranial  
309 Doppler (TCD) and/or duplex Doppler ultrasound. These techniques function based on the same  
310 fundamental principles; however, Duplex ultrasound allows for the simultaneous acquisition of  
311 both blood vessel image and blood velocity (Thomas, Lewis, Hill, & Ainslie, 2015), whereas  
312 TCD only records blood velocity of an insonated blood vessel (Willie et al., 2011). The same  
313 experienced sonographers were used for all studies, and they used commercially available



314 ultrasound machines (TCD, Spencer Technologies, PMD150B; Duplex ultrasound, uSmart 3300,  
315 Terason; Vivid, GE, Fairfield, CT, USA). For our studies, TCD ultrasound utilized a low  
316 frequency probe (2 MHz) to assess blood velocity in the middle and posterior cerebral arteries  
317 using previously described techniques (Willie et al., 2011). Our peripheral Duplex ultrasound  
318 machines used a higher-frequency (10 MHz) linear array probe and were portable with a short  
319 battery life (~90-minutes), therefore, routine access to power supplies were needed. The  
320 peripheral Duplex ultrasound machines were used to measure blood flow through the brachial,  
321 renal, common carotid, internal carotid, external carotid, and vertebral arteries using previously  
322 established guidelines and principles (Thomas et al., 2015). Data backups were performed daily  
323 to multiple portable encrypted solid-state hard drives. In previous high altitude expeditions, our  
324 team has encountered several failures with older spinning hard drives likely due to the reduction  
325 in barometric pressure. Therefore, we ensure that we only use solid-state external and internal  
326 hard drives while at high altitude.

327

328 ***Transthoracic Echocardiography.*** For studies assessing cardiac function and/or pulmonary  
329 pressure, a portable, battery-powered, cardiac ultrasound machine was employed (Vivid Q, GE,  
330 Fairfield, CT, USA). Ultrasound images were acquired and analyzed using a range of  
331 echocardiographic techniques including two-dimensional, Doppler and speckle-tracking  
332 modalities in accordance with published guidelines (Lang et al., 2015; Rudski et al., 2010).  
333 Pulmonary artery systolic pressure (PASP) was a primary outcome variable for a number of  
334 studies, and was measured by Doppler echocardiography based upon measurement of the  
335 maximum velocity of the tricuspid regurgitation jet (Bertini et al., 2009). The peak systolic  
336 pressure gradient of the right ventricle ( $\Delta P$  max) to the right atrium was calculated by the

337 simplified Bernoulli equation ( $4*V^2$ ), where V is the peak systolic velocities of the tricuspid  
338 regurgitate. Pulmonary artery systolic pressure was then determined by adding the right atrial  
339 pressure. Right atrial pressure was estimated by evaluation of the inferior vena cava diameter and  
340 response to a deep inspiration (Aessopos, Farmakis, Taktikou, & Loukopoulos, 2000).

341

342 **Blood sampling.** Blood samples were obtained following placement of an indwelling cannula  
343 located in either a radial/brachial artery, or forearm antecubital vein as required. Blood was  
344 drawn directly into a safePico syringe (Radiometer, Copenhagen, Denmark) for immediate blood  
345 gas analysis (*outlined in detail below*) and into Vacutainers<sup>®</sup> (Becton, Dickinson and Company,  
346 Oxford, UK) containing either K<sub>2</sub>-ethylenediaminetetraacetic acid (K<sub>2</sub>-EDTA), serum separation  
347 gel or sodium citrate, before centrifugation at 600g (4 °C) for 10-minutes. Plasma, serum and red  
348 blood cell slurry were decanted into 2 mL cryogenic vials (Simport<sup>™</sup>, Fischer Scientific Ltd,  
349 UK) and immediately snap frozen and stored in liquid nitrogen (-196 °C) prior to international  
350 transportation back to the United Kingdom, USA, and Canada for specialist batch analyzes.  
351 Worth noting, due to the reduced barometric pressure in Cerro de Pasco, and volume percent of  
352 plasma in individuals with EE, ~twice as many vacutainers were required (compared to typical  
353 low altitude studies) to account for the reduced blood volume collected.

354

355 **Blood gas analysis.** Both venous and arterial blood samples were collected and analyzed by  
356 either a stationary commercial blood gas (ABL90 Flex, Radiometer Canada), or a portable blood  
357 analyzer (i-STAT, Abbot Point of Care, Princeton, New Jersey). Both devices (ABL90 and i-  
358 STAT) have barometric and temperature sensors within to correct for high altitude environments.  
359 The Radiometer ABL90 analyzer aspirates blood samples into a chamber containing electrodes

360 that are selective for the variables of interest. The ABL90 analyzer, although reliable and  
361 functional at altitude, required constant calibration, and encountered numerous blood clots likely  
362 due to a combination of the high volume of blood samples analyzed (~1000 samples) and the  
363 abnormally viscous blood encountered in the EE Andean participants. In general, throughout the  
364 expedition our research team consistently encountered higher than expected blood clotting  
365 incidents in both venous and arterial catheters, especially in the Andeans with EE. It was  
366 interesting to note that several samples obtained from the EE patients were hemolyzed (red tinge  
367 in plasma/serum), which was resolved following isovolemic hemodilution, implicating excessive  
368 polycythemia and increased red blood cell “fragility” as potential contributory factors. The  
369 portable i-STAT devices were used as a back-up in case the ABL90 required flushing or  
370 calibration, and were used for a few select studies that were measuring either venous or arterial  
371 blood (~250 samples in total). Despite the apparent electrical demise of our hot water bath early  
372 in the expedition, we successfully acquired novel measures of blood viscosity after some  
373 technical ingenuity, which involved removing, dismantling, and mending the equipment’s  
374 electrical motor. Following collection into lithium-heparin vacutainers, whole blood viscosity  
375 was measured in duplicate at a shear rate of  $225\text{ s}^{-1}$  and was body temperature corrected using a  
376 cone and plate viscometer (DV2T Viscometer, Brookfield Amtek, USA) (Baskurt et al., 2009;  
377 Gnasso et al., 2001; Tremblay, Howe, Ainslie, & Pyke, 2018).

378

379 ***Blood volume testing.*** Blood volume, plasma volume, and hemoglobin mass was determined  
380 using the modified carbon monoxide rebreathing method, as described previously (Schmidt &  
381 Prommer, 2005), and has been successfully used by our research team (Stembridge et al., 2019).  
382 Briefly, the protocol consisted of a venous blood draw for the determination of hemoglobin

383 concentration and the percentage of carboxyhaemoglobin (HbCO) via co-oximetry (ABL 90,  
384 Radiometer, Denmark). Subsequently, the participants began rebreathing 100% oxygen via a  
385 closed circuit (Bloodtec, GbR, Germany) whilst carbon monoxide was added to the gas mixture  
386 (1.0 ml kg<sup>-1</sup>). Following two-minutes of rebreathing, a second venous blood draw was taken for  
387 the assessment of the same hematological parameters. Hematocrit was assessed via  
388 centrifugation and micro-hematocrit reader. This technique has previously used successful at  
389 high altitude (Ryan et al., 2014), and proven to be reliable against gold standard labelling  
390 techniques (Siebenmann, Keiser, Robach, & Lundby, 2017).

391

392 ***Arterial cannulation and pharmacological infusion.*** After local anesthesia (2% lidocaine) a  
393 4.45-cm, 20 gauge catheter (Arrow, Markham, ON, Canada) was inserted under aseptic  
394 conditions into the brachial artery of the non-dominant arm for local pharmacological infusions  
395 and measurement of mean arterial pressure (MAP). Pharmacological agents were infused using a  
396 standard infusion only syringe pump (PhD Ultra Syringe Pumps, Harvard Apparatus, Holliston,  
397 MA, USA).

398

399 ***Cognitive function.*** Cognitive function was assessed using cognitive performance assessment  
400 software (Cogstate Ltd., Melbourne VIC, Australia). This standardized and automated  
401 computerized battery of neuropsychological tests (W. R. Cole et al., 2013), required participants  
402 to respond to playing cards, which assess different aspects of cognitive function (e.g. attention,  
403 psychomotor performance, working memory). Male and female Andeans who were asked to  
404 complete these neuropsychological tests were provided the Spanish version after the test was  
405 thoroughly explained by one of our local translators.

406

407 *Microneurography*. Muscle sympathetic nerve activity was obtained in either the radial or  
408 peroneal nerve (dependent upon the study) by inserting a Tungsten microelectrode into a muscle  
409 nerve fascicle of a sympathetic nerve bundle and a reference electrode subcutaneously 2–3 cm  
410 from the recording electrode (Mano, Iwase, & Toma, 2006). This technique was conducted by  
411 the same experienced microneurographers. Neural signals were collected using commercially  
412 available recording systems (662C-3, Bioengineering of University of Iowa, Iowa City, IA;  
413 Neuro AMP EX FE185, ADInstruments, Colorado Springs, CO, USA). Common electrical noise  
414 issues were encountered at both sea level and high altitude, and these issues were exaggerated  
415 when using the back-up generator as a power source. Linking the systems to an earth-ground  
416 (fence post in close proximity to the research laboratory) reduced electrical noise issues. One of  
417 the nerve traffic analyzers was part of the equipment locked in Peru customs upon arrival. This  
418 made running two microneurography-based studies problematic at the high altitude laboratory. It  
419 was not until the arrival of this equipment to the laboratory that both microneurography studies  
420 could run simultaneously as originally planned. The nerve signals were amplified (gain 70 000–  
421 160 000), band-pass filtered (700–2000 Hz), full-wave rectified, and integrated with a resistance-  
422 capacitance circuit (time constant 0.1 s). Criteria for adequate MSNA recording included: (1)  
423 pulse synchrony, (2) facilitation during the hypotensive phase of the Valsalva maneuver, and  
424 suppression during the hypertensive overshoot after release, (3) increases in response to breath  
425 holding, and (4) insensitivity to a gentle skin touch or a loud shout (Delius, Hagbarth, Hongell, &  
426 Wallin, 1972). Earphones (Audiotechnica ATH M40x) were used during microneurography  
427 searching to reduce distraction related to ambient noise.

428

429 **Exercise testing.** Maximal cardiopulmonary exercise testing was performed in the semi-  
430 recumbent position on an electronically braked cycle ergometer (Corival Paediatric, Lode B.V.,  
431 Groningen, Netherlands). The bicycle frame that the participant laid on was custom made in  
432 Cerro de Pasco using wood purchased from a local store, and was assembled in the laboratory  
433 using common power tools. The protocol was explained thoroughly by a local translator prior to  
434 the exercise test and participants were instructed to maintain a cadence between 70 and 80 rpm  
435 with verbal feedback given throughout the experiment. Following an initial rest period, the first  
436 stage of exercise was two-minutes in duration at 20 W with subsequent increments of 20 W  
437 every minute until the participant reached volitional exhaustion. Peak power output was  
438 calculated as the 20 W increment divided by 60, multiplied by the time into the last stage and  
439 added to the power output from the last completed stage. Respiratory measures were assessed via  
440 breath-by-breath online gas analysis (Oxycon Mobile, Carefusion, San Diego, CA, USA), heart  
441 rate was recorded using a heart rate strap and transmitted to a Polar Electro RS4000 watch (Polar  
442 Electro, Kemple, Finland), and peripheral oxygen saturation measured via fingertip pulse  
443 oximetry (Choice Mmed, MD300C2, Beijing Choice Electric Technology Co Ltd, Beijing,  
444 China). Peak oxygen consumption ( $VO_{2peak}$ ) was calculated as the highest oxygen uptake ( $VO_2$ )  
445 over a 30-second average. Importantly, these data are only applicable to other studies that  
446 utilized semi-recumbent cycling exercise, and may not be useful when comparing against other  
447 modes of exercise (e.g. trekking, running etc.).

448

449 **Sleep Monitoring.** Sleep architecture was assessed using a wrist-worn ambulatory sleep system  
450 (WatchPat Central Plus, Itamar Medical, Israel). This system incorporates arterial pulsatile  
451 volume changes (via peripheral arterial tone signal) in the finger, pulse oximetry, and actigraphy,

452 to algorithmically evaluate and score metrics of sleep disordered breathing (e.g. apnea-hypopnea  
453 index, oxygen desaturation index, rapid eye movements versus non-rapid eye movements stages  
454 of sleep) (Yalamanchali et al., 2013). These devices have been previously validated to  
455 differentiate between central and obstructive sleep apnea (Pillar et al., 2019), and have been used  
456 at high altitude (Carr et al., 2020; Lipman et al., 2015; Orr et al., 2018). However, these devices  
457 have not been fully validated at high altitude; therefore, the data pertaining to oxygen  
458 desaturation, sleep staging, and apnea-hypopnea index will be cautiously interpreted.  
459 Questionnaires performed before sleep and upon awakening were also conducted to quantify  
460 sleep quality.

461

462 ***Nitric oxide synthesis.*** Nitric oxide (NO) for clinical use was not available in Peru when these  
463 studies were conducted. To overcome this challenge, pure NO was produced in small quantities  
464 from the reaction of sodium nitrite (a common food additive) with hydrochloric acid (Arlin B.  
465 Blood, PhD, personal communication). This reaction produces small quantities of nitric oxide  
466 compounds (NO<sub>x</sub>) such as NO<sub>2</sub> and N<sub>2</sub>O<sub>2</sub> in addition to pure NO gas itself. To eliminate the  
467 other NO<sub>x</sub> compounds, the gas resulting from the initial reaction with acid was mixed with a  
468 solution of sodium hydroxide (NaOH), resulting in pure NO. All the reactions were performed in  
469 an anaerobic environment with the use of 50 ml syringes, initially flushed with nitrogen. The  
470 pure NO immediately diluted with nitrogen to reduce the concentration of NO to a few hundred  
471 parts per million (ppm). Finally, this diluted NO/N<sub>2</sub> was mixed with oxygen immediately before  
472 it was used, to produce a mixture of ~21% oxygen, 79% N<sub>2</sub>, and 40 ppm NO. After verification  
473 of the gas concentrations with analyzers for oxygen and NO, subjects inhaled this mixture from a  
474 Douglas bag for studies #4 and #8 outlined in Table 1.

475

476 ***Blood analysis and transport.*** Approximately 4000 samples were transported back to the  
477 laboratory in Lima for analysis and international shipment, whilst ~200 samples remained in  
478 Lima for the measurement of serum concentrations of iron (trans-ferritin, ferritin, iron, etc.) and  
479 plasma erythropoietin (MedLab, Lima, Peru). The majority of biological samples were  
480 immediately shipped on dry ice (-78.5°C; Marken Ltd; temperature verified) to the United  
481 Kingdom, Canada, and United States for subsequent analysis. These analyses included the  
482 following measurements of systemic endothelial microparticles [including endothelial activation  
483 (i.e., CD62e<sup>+</sup>) and apoptosis (i.e., CD31<sup>+</sup>/42b<sup>-</sup>)] and oxidative-inflammatory-nitrosative-  
484 structural (OXINOS) stress that have previously been described in detail elsewhere (Bailey et al.,  
485 2018; Bailey et al., 2017).

486

487 1. *Oxidative Stress:* Samples will be analyzed for the ascorbate free radical directly using  
488 X-band electron paramagnetic resonance spectroscopy. Serum lipid hydroperoxides will  
489 be assayed spectrophotometrically as complementary biomarkers of lipid peroxidation.  
490 Plasma ascorbic acid and lipid soluble antioxidants will be assayed by fluorimetry and  
491 high-performance liquid chromatography.

492

493 2. *Inflammatory Stress:* high-sensitivity (hs) C-reactive protein and tumor necrosis factor- $\alpha$   
494 will be assayed by hs enzyme-linked immunosorbent assay (ELISA).

495

496 3. *Nitrosative Stress:* Plasma and red blood cell concentrations of nitrite, S-nitrosothiols and  
497 S-nitrosoHb will be determined by ozone-based chemiluminescence. Plasma 3-



498 nitrotyrosine, a biomarker reflecting the oxidative inactivation of NO, will be measured  
499 by hs-ELISA.

500

501 4. *Structural stress*: S100 $\beta$ , neuron-specific enolase, myelin basic protein, neurofilament  
502 light, ubiquitin carboxy-terminal hydrolase-L and glial fibrillary acidic protein  
503 (biomarkers of blood-brain barrier integrity, neuronal-parenchymal damage and glial  
504 damage respectively) will be measured by hs-ELISA.

505

## 506 **Data Analysis**

507 *Sample Size Estimates.* Sample sizes were determined *a priori* based on study specific effect  
508 size estimates. Moreover, based on our research team's previous experience with high altitude  
509 expeditions, adjustments were made to account for expected participant dropout (e.g. (Foster et  
510 al., 2014; Hoiland et al., 2019; Lewis et al., 2014; Simpson et al., 2019; Smith et al., 2014;  
511 Stembridge et al., 2019; Tremblay, Thom, Yang, & Ainslie, 2017; Tymko et al., 2017; Willie et  
512 al., 2014)). Sample sizes were determined using statistical power tests that assumed a minimum  
513 statistical power of 80% (or 0.8). Statistical significance was set at an alpha value of 0.05.  
514 Depending on the variability of the primary outcome of each study, 10-58 study participants  
515 were recruited.

516

517 *Statistics.* Statistical analysis included in the current manuscript was performed using SigmaStat  
518 V13 (Systat, Chicago, IL, USA), and all data are reported as mean  $\pm$  SD. Statistical significance  
519 was set at  $P < 0.05$ . For statistical comparisons between lowlanders at sea level and high altitude,  
520 paired *t*-tests were used (e.g. table 3 and 4). For statistical comparisons between male lowlanders

521 at high altitude, and male Andean (EE+ and EE-), a one-way analysis of variance design was  
522 used. For statistical comparison between male and female healthy (i.e., non-EE) Andeans, un-  
523 paired *t*-tests were used. When significant F-ratios were detected, differences between means  
524 were determined using Bonferonni-corrected independent samples *t*-tests.

525

526 **General Results and Characterization of Cohorts**

527 ***Studies conducted and participants recruited.*** In total, 15 separate *a priori* studies (see table 1),  
528 amounting to >780 study sessions were completed between sea level testing in Kelowna, BC,  
529 Canada (344m), and over ~25 days in Cerro de Pasco (4300m). This amounted to 829  
530 experimental hours in lowlanders at sea level, 1522 experimental hours in lowlanders at high  
531 altitude, 500 experimental hours in non-EE Andean highlanders, and 219.75 experimental hours  
532 in Andean highlanders with EE. Table 2 highlights the participant demographics (age, height,  
533 weight and body mass index) for lowlanders (n=30), and highlanders with (n=22; all male) and  
534 without (n=45; 11 female) EE.

535

536 ***Arterial blood data (lowlanders and Andeans).*** Table 3 displays arterial blood data obtained in  
537 13 male lowlanders at sea level (Lima, Peru) immediately prior to ascending to Cerro de Pasco,  
538 and after 14 days of high altitude exposure. In addition, table 3 illustrates baseline arterial blood  
539 data in 16 male Andean participants with and without EE at 4300m. Compared to sea-level,  
540 lowlanders after 14 days of high altitude acclimatization had higher pH, but lower PaCO<sub>2</sub>, PaO<sub>2</sub>,  
541 SaO<sub>2</sub> and HCO<sub>3</sub><sup>-</sup> (all P<0.001). Lowlanders after 14 days of high altitude exposure had an  
542 elevated arterial blood pH and SaO<sub>2</sub> compared to Andeans with EE (P<0.01). Lowlanders at  
543 altitude had lower PaCO<sub>2</sub> and HCO<sub>3</sub><sup>-</sup> compared to EE Andean participants (both P<0.001).  
544 Lowlanders at high altitude had the same arterial blood pH (P=0.316), PaCO<sub>2</sub> (P=1.00), PaO<sub>2</sub>  
545 (P=1.00), HCO<sub>3</sub><sup>-</sup> (P=1.00), and SaO<sub>2</sub> (P=1.00) compared to non-EE male Andean participants.  
546 Compared to non-EE male Andean participants, Andeans with EE had a lower arterial blood pH  
547 (P=0.014) and SaO<sub>2</sub> (P<0.001), but an elevated PaCO<sub>2</sub>, and HCO<sub>3</sub><sup>-</sup> (both P<0.001). There were  
548 no differences in PaO<sub>2</sub> observed between male Andeans with and without EE (P=0.087) with our

549 statistical model (Lowlanders vs Andeans); however, when a less conservative unpaired t-test  
550 was performed between male Andean groups, Andeans with EE had a lower PaO<sub>2</sub> compared to  
551 non-EE Andeans (P=0.03). In Figure 2, a proton-bicarbonate (i.e. Davenport) diagram was used  
552 to demonstrate the various acid–base compensation and comparisons between groups.

553

554 ***Venous blood data (lowlanders and Andeans).*** Table 4 displays venous blood data obtained in  
555 male lowlanders at sea-level (n=24; Kelowna, BC), and after 14 days of high altitude exposure  
556 (n=17). In addition, table 4 illustrates baseline venous blood data in male Andean participants  
557 with EE (n=21), males and female Andeans without EE (n=26 and n=11, respectively). After 14  
558 days of high altitude acclimatization, lowlanders had an increase in hemoglobin and blood  
559 viscosity compared to sea level values (both P<0.001). Lowlanders at altitude had lower  
560 hemoglobin and blood viscosity compared to male Andean with EE (both P<0.001), and  
561 Andeans without EE (both P<0.001). Male Andean EE participants had higher hemoglobin and  
562 blood viscosity compared to non-EE Andeans (both P<0.001). Notably, four participants' (all  
563 EE+; Hb of these participants = 24.7±1.1 g dL<sup>-1</sup>) blood viscosity *exceeded* the upper limit of the  
564 viscometer (>10.22 cP), thus, their blood viscosity was reported as 10.22 cP. Female Andeans  
565 had lower hemoglobin and blood viscosity compared to male Andeans without EE (P=0.007 and  
566 P=0.004, respectively).

567

568 ***Exercise performance (lowlanders and Andeans).*** Figure 3 displays exercise performance data  
569 between lowlanders at sea level, lowlanders at high altitude, Andean male participants with and  
570 without EE, and Andean female participants. At high altitude, lowlanders had a lower absolute  
571 and relative VO<sub>2</sub> max (P=0.001), and peak power output (P<0.001), compared to sea level

572 values. Lowlanders at high altitude had an elevated peak power output compared to male  
573 Andeans with EE ( $P<0.001$ ) and non-EE Andeans ( $P<0.001$ ). Absolute  $\text{VO}_2$  max was higher in  
574 lowlanders at high altitude compared to male Andean participants with ( $P=<0.001$ ) and without  
575 EE ( $P<0.001$ ). Relative  $\text{VO}_2$  max was similar in lowlanders at high altitude compared to male  
576 Andean participants with ( $P=0.619$ ) and without EE ( $P=0.492$ ). No differences in absolute  $\text{VO}_2$   
577 max ( $P=0.91$ ), and relative  $\text{VO}_2$  max and peak wattage were observed between male Andean  
578 participants (both  $P=1.00$ ). Female Andeans had a similar relative  $\text{VO}_2$  max ( $P=1.00$ ), and a  
579 lower absolute  $\text{VO}_2$  max ( $P=0.001$ ), and peak wattage compared to non-EE male Andeans  
580 ( $P=0.015$ ).

581

582

583 **Discussion**

584 Despite some of the major obstacles encountered during the expedition outlined throughout this  
585 manuscript, our research team, Global REACH, collected ~90% of the data for the proposed  
586 projects. Below we outline some of the lessons learnt from this expedition and discuss in further  
587 detail the expected forthcoming publications, and finally, discuss the potential clinical translation  
588 and future goals of the Global REACH research team.

589

590 *Major challenges.* The success of large-scale field research expeditions typically depends on  
591 establishing appropriate and adequate local support. Through a historical connection, our  
592 research team was capable of organizing contact with local Peru collaborators: Dr. Francisco  
593 Villafuerte and his laboratory team consisting of graduate students and administrators. Six  
594 months prior to the research expedition, two members of Global REACH traveled to Cerro de  
595 Pasco to collect some preliminary data and construct initial planning for our core studies with  
596 our local collaborators. Without the local Peruvian team and their unfailing help and support,  
597 several aspects of the expedition would not have been possible including: 1) recruitment of  
598 Andean highlanders using their established database, 2) organizing transport to the high altitude  
599 laboratory in Cerro de Pasco, and 3) local ethical approval for all proposed studies. Our team had  
600 full-time access to multiple graduate students of Dr. Villafuerte who handled nearly all  
601 recruitment and screening of participants and offered their skills of being a translator between the  
602 study principal investigators and Andean study participants.

603 During our Nepal expedition in 2016, our research team collected data upon ascent to  
604 high altitude (5050m) without the confounding influence of participants taking prophylactic  
605 acetazolamide (Willie et al., 2018). In order for our data to remain consistent between our Nepal

606 and Peru high altitude expeditions, we aimed to refrain from taking any high altitude  
607 medications. However, if participants fell severely ill from altitude and/or non-altitude related  
608 sickness, our physicians had adequate medication available for treatment. Unlike our expedition  
609 in Nepal, which involved a gradual ascent to 5050m over a period of ~7-10 days, we were  
610 transported to altitude by automobile over a 7-8 hour rapid ascent to Cerro de Pasco. Due to this,  
611 nearly all participants reported symptoms of acute mountain sickness (via Lake Louise scoring  
612 system), with several having to be treated with Acetazolamide after arrival (n=6). No participants  
613 had to be evacuated due to altitude related illness; however, these individuals were either  
614 removed from specific studies due to illness or were rescheduled to participate once they were  
615 fully recovered and endured a complete drug washout time (i.e. at least five half-lives).

616         Lastly, the biggest challenge of this expedition was the logistical aspect of transportation  
617 and importation of research equipment. Unfortunately, despite a substantial effort to organize  
618 and submit importation documents for legal entry into Peru, a large portion of our equipment was  
619 initially rejected entry into Peru. Rectifying this issue required countless hours and financial  
620 assurances from the local university to release this equipment. This unforeseen complication  
621 resulted in the delay of multiple research projects; however, through equipment sharing and  
622 working excessive hours, our research team was able to cope with the temporary equipment loss  
623 until it arrived ~14 days after arrival to Cerro de Pasco. For these reasons, we recommend future  
624 expeditions to bring back-up and duplicate equipment whenever possible in case of any  
625 equipment issues related to foreign country importation.

626

627 *Arterial blood gases and acid-base balance.* When a lowlander travels to high altitude,  
628 hyperventilation occurs as a result from hypoxemia associated peripheral chemoreceptor

629 stimulation, the PaCO<sub>2</sub> falls, and the arterial blood pH rises in accordance with the Henderson–  
630 Hasselbach equation:

631

$$\text{pH} = \text{pK} + \log \frac{[\text{HCO}_3^-]}{0.03\text{PaCO}_2}$$

632

633 *Equation 1: Henderson-Hasselbach equation where [HCO<sub>3</sub><sup>-</sup>] is the bicarbonate*  
634 *concentration in millimoles per liter and the PaCO<sub>2</sub> is in mmHg.*

635

636 However, the kidney responds by eliminating bicarbonate, which is prompted via reductions in  
637 PCO<sub>2</sub> in the renal tubular cells. This results in a more alkaline urine due to decreased  
638 reabsorption of bicarbonate ions. The decrease in plasma bicarbonate then moves the  
639 bicarbonate/PaCO<sub>2</sub> ratio back towards its normal equilibrium. This relationship is known as  
640 metabolic compensation for respiratory alkalosis. The compensation may be complete, in which  
641 case the arterial pH returns to ~7.40 or, more often, incomplete with a steady-state pH that  
642 exceeds ~7.40. There are two noteworthy and novel observations from the arterial blood gas data  
643 (*see Table 3*). First, two-weeks of acclimatization at 4300m in lowlanders resulted in comparable  
644 changes in SaO<sub>2</sub>, PaO<sub>2</sub>, PaCO<sub>2</sub>, and HCO<sub>3</sub><sup>-</sup> when compared to non-EE Andean highlanders who  
645 have resided at this elevation for many years. In contrast, despite the comparable changes in  
646 PaCO<sub>2</sub> (and hence likely stimulus to reduce HCO<sub>3</sub><sup>-</sup>), pH remained elevated in lowlanders. Thus,  
647 despite comparable oxygenation and metabolic compensation in the Andeans – as indexed via  
648 HCO<sub>3</sub><sup>-</sup> – it failed to compensate for the respiratory alkalosis (i.e., elevated pH; *refer to figure 2*).  
649 It is possible that these results could be directly due to differences in strong base ions since  
650 differences in standard base excess can alter blood pH for a given PaCO<sub>2</sub> (Morgan, 2009).



651 Unfortunately, we did not acquire standard base ion in lowlanders at this time-point since these  
652 blood samples were analyzed using iSTAT cartridges that did not output these data. Also of note  
653 was that the female Andeans had a lower blood Hb and viscosity compared to non-EE male  
654 Andean highlanders. These results align with previous findings demonstrating that  
655 premenopausal female highlanders have lower incidences of CMS and EE, which may be related  
656 to elevated levels of progesterone during their menstrual cycle resulting in elevated ventilation,  
657 thus SaO<sub>2</sub> – a primary stimulus for red blood cell production (Leon-Velarde et al., 1997; Leon-  
658 Velarde, Rivera-Chira, Tapia, Huicho, & Monge, 2001).

659 Albeit over a shorter period, the time course of the change in arterial pH when normal  
660 subjects ascend abruptly to high altitude has been studied by several investigators (Dempsey,  
661 Forster, Chosy, Hanson, & Reddan, 1978; Lenfant, Torrance, & Reynafarje, 1971; Severinghaus,  
662 Mitchell, Richardson, & Singer, 1963). In one study, lowlanders were taken within five hours  
663 from sea level to an altitude of 4509m (P<sub>B</sub> = 446 mmHg) and remained there for four days. The  
664 arterial pH rose to a mean of about 7.47 within 24-hours and then gradually declined but was still  
665 ~7.45 at the end of the four-day period (Lenfant et al., 1971). In another study, four normal  
666 subjects were taken abruptly to 3800m for eight days. The arterial pH rapidly rose from a mean  
667 of 7.424 at sea level to 7.485 after two days, and remained constant, being 7.484 at the end of  
668 eight days (Severinghaus et al., 1963). In a further study, 11 lowlanders traveled to 3200m  
669 altitude where they remained for 10 days (Dempsey et al., 1978). The arterial pH rose by 0.03–  
670 0.04 units within two days, and then remained essentially unchanged. In all instances, the PaCO<sub>2</sub>  
671 continued to decline as did the plasma bicarbonate concentration. Consistent with the current  
672 data, it appears that the return of the arterial pH to (or near to) its sea level value is very slow and  
673 may not occur even after years of exposure to high altitude (as confirmed by the elevated pH

674 observed in non-EE Andeans). Some studies have collected arterialized blood indirectly (e.g. ear  
675 lobe and finger) to measure acid-base balance during short term (Samaja, Mariani, Prestini, &  
676 Cerretelli, 1997), and long-term exposure to high altitude (Porcelli et al., 2017). In one study,  
677 arterialized ear lobe blood pH was elevated at 5050m and remained elevated for three-weeks in  
678 lowlanders (Samaja et al., 1997), while in another study conducted at the equivalent of ~3800m  
679 arterialized finger capillary blood pH remained elevated for 300 days (Porcelli et al., 2017).  
680 There are some aspects to our data that make ours unique compared to previous reports: 1) we  
681 collected actual arterial blood from the radial artery; and 2) we report data from a large  
682 participant cohort and arterial blood samples were taken at the exact same time point (sea-level,  
683 day 1, and day 14), after a controlled ascent to 4300m, while refraining from altitude illness  
684 medications.

685 Another interesting observation consistent with previous reports is the relative  
686 hypoventilation in the EE Andeans, as reflected in the arterial hypoxemia and attenuated  
687 reductions in PaCO<sub>2</sub> compared to the non-EE Andean and lowlander groups (Beall, 2006). The  
688 mechanism(s) driving this relative hypoventilation has been explained in detail elsewhere  
689 (Villafuerte & Corante, 2016). Nevertheless, it is interesting to note that despite this greater  
690 hypoxemia and attenuated reductions in PaCO<sub>2</sub>, the greater reductions in HCO<sub>3</sub><sup>-</sup> resulted in full  
691 metabolic compensation for the respiratory alkalosis i.e., comparable pH in Andeans with EE to  
692 lowlanders at sea level. Worth noting, Davenport diagrams (e.g. *figure 2*) provide only basic  
693 insight into acid-base derangements at high altitude; therefore, one of our future goals is to  
694 collect additional data to employ more sophisticated acid-base models to better understand this  
695 important physiology.

696

697 ***Exercise performance.*** Similar to previous reports, our data indicate that exercise performance  
698 (both relative VO<sub>2</sub> max and peak wattage) is reduced with high altitude exposure in lowlanders  
699 (Cymerman et al., 1989; Smith et al., 2014; Tymko et al., 2017; Wehrlin & Hallen, 2006). Our  
700 exercise data in male Andean highlanders supports previously published data that indicate that  
701 Andeans with EE have a similar VO<sub>2</sub> max and peak wattage compared to non-EE male Andean  
702 participants despite substantially elevated Hb and reduced SaO<sub>2</sub> (Groepenhoff et al., 2012;  
703 Swenson, 2012). To ensure all lowlander and highlander participants performed a maximal effort  
704 during the exercise protocol verbal encouragement was provided by several research personnel  
705 and at least one Spanish translator. In addition, although the statistical differences detected  
706 between groups (lowlanders and highlanders) were different for relative VO<sub>2</sub> max and peak  
707 wattage (*refer to figure 3*), the mean trends between groups were similar.

708

709 ***Comparison to Nepal 2016 expedition.*** Although the fundamental goals of our international  
710 research team's expeditions to Nepal and Peru were similar, there are distinct differences  
711 between these two expeditions that warrant further comment. First, there were a large number of  
712 "ascent" studies conducted in both lowlanders and Sherpa over a gradual ascent to a slightly  
713 higher altitude (5050m vs 4300m). The Sherpa studied during the ascent investigations  
714 permanently lived at altitudes >3500m within the Khumbu valley, and were requested to descend  
715 to Kathmandu (1400m) for  $9 \pm 3$  days prior to gradual ascent with the research team to the  
716 pyramid laboratory. Reasoning for this was to partially de-acclimatize the Sherpa from an  
717 autonomic, endocrine, cardiovascular, and respiratory standpoint; however, the descent and re-  
718 ascent altitude profile likely did not alter the Sherpa's hemoglobin concentration since the life  
719 cycle of red blood cells is ~three months (Berlin, Waldmann, & Weissman, 1959).

720 In Nepal, our research team also tested a large cohort of Sherpa at 5050m that did not  
721 descend to lower altitude in a number of studies, but these Sherpa also resided permanently at  
722 altitudes >3500m within the Khumbu valley. Another important consideration is the difference in  
723 lifestyles and environment between Nepal and Peru. Our Sherpa cohort, by nature, were likely to  
724 be more physically active compared to the Andeans, having to walk long distances on a daily  
725 basis and serving as guides in nearby mountains. Nevertheless, previous reports indicate similar  
726 rates of obesity between Sherpa and Andean highlanders (~10% vs ~8%, respectively; (Sherpa et  
727 al., 2010; Woolcott et al., 2016)). It is also worth acknowledging that our Andean highlanders  
728 had access to a greater variety of food in Cerro de Pasco compared to the Sherpa in the Khumbu  
729 valley.

730

731 ***Clinical Translation.*** Research on high altitude physiology offers complementary insight into  
732 biological adaptation to hypoxia. Ways to apply results from these expeditions are multifaceted,  
733 with implications for military deployment to high altitude (e.g. Afghanistan), for the growing  
734 numbers (>1 million) of lowlanders vacationing at high altitude destinations, and for commercial  
735 flight personnel who are hypoxic during flight (mild hypoxia). These data can have direct  
736 translational impact for patients in critical care and in other clinical situations of chronic hypoxia  
737 (e.g. lung disease, heart failure, circulatory shock). For example, we observed that several blood  
738 samples obtained from Andeans with EE were “hemolyzed”, which was resolved following  
739 isovolemic hemodilution. Importantly, these research expeditions will give us novel insight into  
740 the current physiological status of local highlanders (Tibetan, Peruvian, and Ethiopian), which  
741 may lead to related health benefits in these populations. The results from this study will be a  
742 valuable step toward effective treatments for the potential cardiopulmonary consequences of EE.

743

744 *The future of Global REACH.* Due to the numerous publications, the local cultural benefit (e.g.  
745 CMS and EE research), the international scientific relationships gained (e.g. Dr. Villafuerte), and  
746 the opportunity for training highly qualified personnel with each expedition (e.g. graduate and  
747 medical student training), our research team, Global REACH, intends to organize future large-  
748 scale high altitude research expeditions. We know significantly less about high altitude related  
749 adaptation in the Ethiopian Amhara and Oromo highlanders from the Simien and Bale  
750 mountains, respectively. The Amhara have hemoglobin concentrations similar to lowlanders, yet  
751 higher than expected oxygen saturation, potentially due to an increased affinity of their  
752 hemoglobin for oxygen (Beall, 2006; Beall et al., 2002). Only few sophisticated physiological  
753 data sets exist on Ethiopian highlanders. Conceivably, the Sherpa, Quechua, and Amhara  
754 phenotypes represent distinct evolution-driven strategies that permit survival and performance at  
755 high altitude. Ethiopia will be the final installment in Global REACH's trilogy of high altitude  
756 adaptation studies.

757

## 758 **Conclusion**

759 The 2018 Global REACH expedition to Peru was comprised of 15 independent studies on three  
760 distinct cohorts: lowlanders (n=30), non-EE Andeans (n=45), and Andeans diagnosed with EE  
761 (n=22). Studies were conducted at sea level (Kelowna, BC; 344mm) and after ascending to Cerro  
762 de Pasco (4300 m) from Lima (~80 m) over a 7-8 hour automobile ride, which focused on  
763 cardiovascular, cerebrovascular, cardiopulmonary, autonomic and neurocognitive aspects of  
764 human physiological responses to hypobaric hypoxia acclimatization. The findings from this

765 study will be reported in several forthcoming publications according to their respective *a priori*  
766 hypotheses.  
767

768 **Declarations**

769 **Ethics approval and consent to participant.** In accordance with the *Declaration of Helsinki*,  
770 the lowlander and highlander based studies were approved by the UBC Clinical Research Ethics  
771 Board (H17-02687 and H18-01404, respectively), and local Peruvian ethics committee for the  
772 Universidad Peruana Cayetano Heredia (#101686). All lowlander and highlander study  
773 participants signed the approved consent form (English and Spanish forms were available) after  
774 each study was thoroughly explained in their native language.

775

776 **Availability of data and material.** The datasets used and/or analyzed during the current study  
777 are available from the corresponding author on reasonable request.

778

779 **Competing interests.** We have no competing interests to declare.

780

781 **Funding.** The 2018 Global REACH expedition to Peru was funded, in part, by a Canada  
782 Research Chair (CRC) and the Natural Sciences and Engineering Research Council (NSERC) to  
783 PNA.

784

785 **Authors' contributions.** M.M.T. and P.N.A were responsible for the concept of the manuscript.  
786 All authors contributed to the analysis, interpretation of the data, along with drafting the article  
787 or critically revising it for important intellectual content. All authors approved the final version  
788 of the manuscript and all person designated as authors qualify for authorship, and all those who  
789 qualify for authorship are listed.

790

791 **Acknowledgements:** The success of this expedition is directly attributed to the team member's  
792 impressive problem solving abilities and resiliency. We would like to give thanks to our local  
793 Peru collaborators for their support in the weeks leading up to, and during data collection in  
794 Peru. The authors are grateful to all other members and participants of the 2018 Global REACH  
795 expedition to Peru: Tyler Vermeulen, Alexander Hansen, Courtney Tymko, Andrew Steele,  
796 Florian Hofstatter, Simon Rainer, Joseph Donnelly, Lisa Wong, Victoria Meah, Kaitlyn Tymko,  
797 Rachel Stone, Lydia Simpson, Christopher Hearon, Sachin Amin, Suman Thapamagar, Gilberto  
798 Moralez, Aimee Drane, John Atkins, Alex Williams, Antoinette Santoro, Daniela Bermudez  
799 Pumasunco, and Romulo Joseph Figueroa Mujica.

800

801



802 **References**

- 803
- 804 Aessopos, A., Farmakis, D., Taktikou, H., & Loukopoulos, D. (2000). Doppler-determined peak  
805 systolic tricuspid pressure gradient in persons with normal pulmonary function and  
806 tricuspid regurgitation. *Journal of the American Society of Echocardiography*, *13*(7),  
807 645-649. doi:10.1067/mje.2000.104535
- 808 Aldenderfer, M. S. (2003). Moving Up in the World: Archaeologists seek to understand how and  
809 when people came to occupy the Andean and Tibetan plateaus. *American Scientist*, *91*(6),  
810 542-549. Retrieved from <http://www.jstor.org/stable/27858304>
- 811 Aldenderfer, M. S. (2008). High elevation foraging societies. In *Handbook of South American*  
812 *Archaeology*, ed. HG Silverman, WH Isbell, pp. 131–43. New York: Springer
- 813 Alkorta-Aranburu, G., Beall, C. M., Witonsky, D. B., Gebremedhin, A., Pritchard, J. K., & Di  
814 Rienzo, A. (2012). The Genetic Architecture of Adaptations to High Altitude in Ethiopia.  
815 *PLOS Genetics*, *8*(12), e1003110. doi:10.1371/journal.pgen.1003110
- 816 Bailey, D. M., Rasmussen, P., Evans, K. A., Bohm, A. M., Zaar, M., Nielsen, H. B., . . . Secher,  
817 N. H. (2018). Hypoxia compounds exercise-induced free radical formation in humans;  
818 partitioning contributions from the cerebral and femoral circulation. *Free Radical and*  
819 *Biology Medicine*, *124*, 104-113. doi:10.1016/j.freeradbiomed.2018.05.090
- 820 Bailey, D. M., Rasmussen, P., Overgaard, M., Evans, K. A., Bohm, A. M., Seifert, T., . . .  
821 Secher, N. H. (2017). Nitrite and S-Nitrosohemoglobin Exchange Across the Human  
822 Cerebral and Femoral Circulation: Relationship to Basal and Exercise Blood Flow  
823 Responses to Hypoxia. *Circulation*, *135*(2), 166-176.  
824 doi:10.1161/circulationaha.116.024226
- 825 Bailey, D. M., Rimoldi, S. F., Rexhaj, E., Pratali, L., Salinas Salmon, C., Villena, M., . . . Sartori,  
826 C. (2013). Oxidative-nitrosative stress and systemic vascular function in highlanders with  
827 and without exaggerated hypoxemia. *Chest*, *143*(2), 444-451. doi:10.1378/chest.12-0728
- 828 Baskurt, O. K., Boynard, M., Cokelet, G. C., Connes, P., Cooke, B. M., Forconi, S., . . . Wautier,  
829 J. L. (2009). New guidelines for hemorheological laboratory techniques. *Clinical*  
830 *Hemorheology and Microcirculation*, *42*(2), 75-97. doi:10.3233/ch-2009-1202
- 831 Beall, C. M. (2006). Andean, Tibetan, and Ethiopian patterns of adaptation to high-altitude  
832 hypoxia. *Integrative and Comparative Biology*, *46*(1), 18-24. doi:10.1093/icb/icj004
- 833 Beall, C. M. (2007a). Detecting natural selection in high-altitude human populations. *Respiratory*  
834 *Physiology and Neurobiology*, *158*(2-3), 161-171. doi:10.1016/j.resp.2007.05.013
- 835 Beall, C. M. (2007b). Two routes to functional adaptation: Tibetan and Andean high-altitude  
836 natives. *Proceedings of the National Academy of Sciences of the United States of*  
837 *America*, *104 Suppl 1*, 8655-8660. doi:10.1073/pnas.0701985104
- 838 Beall, C. M. (2013). Human adaptability studies at high altitude: research designs and major  
839 concepts during fifty years of discovery. *American Journal of Human Biology*, *25*(2),  
840 141-147. doi:10.1002/ajhb.22355
- 841 Beall, C. M., Decker, M. J., Brittenham, G. M., Kushner, I., Gebremedhin, A., & Strohl, K. P.  
842 (2002). An Ethiopian pattern of human adaptation to high-altitude hypoxia. *v*, *99*(26),  
843 17215-17218. doi:10.1073/pnas.252649199
- 844 Berlin, N. I., Waldmann, T. A., & Weissman, S. M. (1959). Life Span of Red Blood Cell.  
845 *Physiological Reviews*, *39*(3), 577-616. doi:10.1152/physrev.1959.39.3.577
- 846 Bermudez, D., Azad, P., Figueroa-Mujica, R., Vizcardo-Galindo, G., Corante, N., Guerra-  
847 Giraldez, C., . . . Villafuerte, F. C. (2019). Increased hypoxic proliferative response and

848 gene expression in erythroid progenitor cells of Andean highlanders with Chronic  
849 Mountain Sickness. *American Journal of Physiology Regulatory Integrative and*  
850 *Comparative Physiology*. doi:10.1152/ajpregu.00250.2019

851 Bertini, M., Sengupta, P. P., Nucifora, G., Delgado, V., Ng, A. C., Marsan, N. A., . . . Bax, J. J.  
852 (2009). Role of left ventricular twist mechanics in the assessment of cardiac  
853 dyssynchrony in heart failure. *Journal of the American College of Cardiology*  
854 *cardiovascular imaging*, 2(12), 1425-1435. doi:10.1016/j.jcmg.2009.09.013

855 Carr, J., Stone, R. M., Tymko, C., Tymko, K., Coombs, G. B., Hoiland, R., . . . Patrician, A.  
856 (2020). Global REACH 2018: The effect of an expiratory resistance mask with deadspace  
857 on sleep and acute mountain sickness during acute exposure to hypobaric hypoxia. *High*  
858 *Alt Med Biol*. IN PRESS.

859 Cole, A. M., Petousi, N., Cavalleri, G. L., & Robbins, P. A. (2014). Genetic variation in SENP1  
860 and ANP32D as predictors of chronic mountain sickness. *High Altitude Medicine and*  
861 *Biology*, 15(4), 497-499. doi:10.1089/ham.2014.1036

862 Cole, W. R., Arrioux, J. P., Schwab, K., Ivins, B. J., Qashu, F. M., & Lewis, S. C. (2013). Test-  
863 retest reliability of four computerized neurocognitive assessment tools in an active duty  
864 military population. *Archives of clinical neuropsychology*, 28(7), 732-742.  
865 doi:10.1093/arclin/act040

866 Cymerman, A., Reeves, J. T., Sutton, J. R., Rock, P. B., Groves, B. M., Malconian, M. K., . . .  
867 Houston, C. S. (1989). Operation Everest II: maximal oxygen uptake at extreme altitude.  
868 *Journal of Applied Physiology (1985)*, 66(5), 2446-2453.  
869 doi:10.1152/jap.1989.66.5.2446

870 Delius, W., Hagbarth, K. E., Hongell, A., & Wallin, B. G. (1972). Manoeuvres affecting  
871 sympathetic outflow in human muscle nerves. *Acta Physiologica Scandinavica*, 84(1),  
872 82-94. doi:10.1111/j.1748-1716.1972.tb05157.x

873 Dempsey, J. A., Forster, H. V., Chosy, L. W., Hanson, P. G., & Reddan, W. G. (1978).  
874 Regulation of CSF[HCO<sub>3</sub><sup>-</sup>] during long-term hypoxic hypocapnia in man. *Journal of*  
875 *applied physiology: respiratory, environmental and exercise physiology*, 44(2), 175-182.  
876 doi:10.1152/jap.1978.44.2.175

877 Foster, G. E., Ainslie, P. N., Stembridge, M., Day, T. A., Bakker, A., Lucas, S. J., . . . Lovering,  
878 A. T. (2014). Resting pulmonary haemodynamics and shunting: a comparison of sea-  
879 level inhabitants to high altitude Sherpas. *Journal of Physiology*, 592(6), 1397-1409.  
880 doi:10.1113/jphysiol.2013.266593

881 Gassmann, M., Mairbaur, H., Livshits, L., Seide, S., Hackbusch, M., Malczyk, M., . . .  
882 Muckenthaler, M. U. (2019). The increase in hemoglobin concentration with altitude  
883 varies among human populations. *Annals of the New York Academy of Sciences*, 1450(1),  
884 204-220. doi:10.1111/nyas.14136

885 Gilbert-Kawai, E. T., Milledge, J. S., Grocott, M. P., & Martin, D. S. (2014). King of the  
886 mountains: Tibetan and Sherpa physiological adaptations for life at high altitude.  
887 *Physiology (Bethesda)*, 29(6), 388-402. doi:10.1152/physiol.00018.2014

888 Gnasso, A., Carallo, C., Irace, C., De Franceschi, M. S., Mattioli, P. L., Motti, C., & Cortese, C.  
889 (2001). Association between wall shear stress and flow-mediated vasodilation in healthy  
890 men. *Atherosclerosis*, 156(1), 171-176. doi:10.1016/s0021-9150(00)00617-1

891 Groepenhoff, H., Overbeek, M. J., Mule, M., van der Plas, M., Argiento, P., Villafuerte, F. C., . .  
892 . Naeije, R. (2012). Exercise pathophysiology in patients with chronic mountain sickness

893 exercise in chronic mountain sickness. *Chest*, 142(4), 877-884. doi:10.1378/chest.11-  
894 2845

895 Haas, R., Stefanescu, I. C., Garcia-Putnam, A., Aldenderfer, M. S., Clementz, M. T., Murphy, M.  
896 S., . . . Watson, J. T. (2017). Humans permanently occupied the Andean highlands by at  
897 least 7 ka. *Royal Society of Open Science*, 4(6), 170331. doi:10.1098/rsos.170331

898 Hoiland, R. L., Howe, C. A., Carter, H. H., Tremblay, J. C., Willie, C. K., Donnelly, J., . . .  
899 Ainslie, P. N. (2019). UBC-Nepal expedition: phenotypical evidence for evolutionary  
900 adaptation in the control of cerebral blood flow and oxygen delivery at high altitude.  
901 *Journal of Physiology*, 597(12), 2993-3008. doi:10.1113/jp277596

902 Horscroft, J. A., Kotwica, A. O., Laner, V., West, J. A., Hennis, P. J., Levett, D. Z. H., . . .  
903 Murray, A. J. (2017). Metabolic basis to Sherpa altitude adaptation. *Proceedings of the  
904 National Academy of Science U S A*, 114(24), 6382-6387. doi:10.1073/pnas.1700527114

905 Hsieh, M. M., Callacondo, D., Rojas-Camayo, J., Quesada-Olarte, J., Wang, X., Uchida, N., . . .  
906 Tisdale, J. F. (2016). SENP1, but not fetal hemoglobin, differentiates Andean highlanders  
907 with chronic mountain sickness from healthy individuals among Andean highlanders.  
908 *Experimental Hematology*, 44(6), 483-490.e482. doi:10.1016/j.exphem.2016.02.010

909 Lang, R. M., Badano, L. P., Mor-Avi, V., Afilalo, J., Armstrong, A., Ernande, L., . . . Voigt, J. U.  
910 (2015). Recommendations for cardiac chamber quantification by echocardiography in  
911 adults: an update from the American Society of Echocardiography and the European  
912 Association of Cardiovascular Imaging. *Journal of American Society of  
913 Echocardiography*, 28(1), 1-39.e14. doi:10.1016/j.echo.2014.10.003

914 Lenfant, C., Torrance, J. D., & Reynafarje, C. (1971). Shift of the O<sub>2</sub>-Hb dissociation curve at  
915 altitude: mechanism and effect. *Journal of Applied Physiology*, 30(5), 625-631.  
916 doi:10.1152/jappl.1971.30.5.625

917 Leon-Velarde, F., Maggiorini, M., Reeves, J. T., Aldashev, A., Asmus, I., Bernardi, L., . . .  
918 Zubieta-Calleja, G. (2005). Consensus statement on chronic and subacute high altitude  
919 diseases. *High Altitude Medicine and Biology*, 6(2), 147-157.  
920 doi:10.1089/ham.2005.6.147

921 Leon-Velarde, F., Ramos, M. A., Hernandez, J. A., De Idiaquez, D., Munoz, L. S., Gaffo, A., . . .  
922 Monge, C. (1997). The role of menopause in the development of chronic mountain  
923 sickness. *American Journal of Physiology*, 272(1 Pt 2), R90-94.  
924 doi:10.1152/ajpregu.1997.272.1.R90

925 Leon-Velarde, F., Rivera-Chira, M., Tapia, R., Huicho, L., & Monge, C. C. (2001). Relationship  
926 of ovarian hormones to hypoxemia in women residents of 4,300 m. *American journal of  
927 physiology. Regulatory, integrative and comparative physiology*, 280(2), R488-493.  
928 doi:10.1152/ajpregu.2001.280.2.R488

929 Levett, D. Z., Martin, D. S., Wilson, M. H., Mitchell, K., Dhillon, S., Rigat, F., . . . Grocott, M.  
930 P. (2010). Design and conduct of Caudwell Xtreme Everest: an observational cohort  
931 study of variation in human adaptation to progressive environmental hypoxia. *BMC  
932 medical research methodology*, 10, 98. doi:10.1186/1471-2288-10-98

933 Lewis, N. C. S., Bailey, D. M., duManoir, G. R., Messinger, L., Lucas, S. J. E., Cotter, J. D., . . .  
934 Ainslie, P. N. (2014). Conduit artery structure and function in lowlanders and native  
935 highlanders: relationships with oxidative stress and role of sympathoexcitation. *The  
936 Journal of Physiology*, 592(5), 1009-1024. doi:10.1113/jphysiol.2013.268615

937 Lipman, G. S., Kanaan, N. C., Phillips, C., Pomeranz, D., Cain, P., Fontes, K., . . . Walsh, D.  
938 (2015). Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-  
939 AID). *High Altitude Medicine and Biology*, 16(2), 154-161. doi:10.1089/ham.2014.1110  
940 Liu, J., Liu, Y., Ren, L. H., Li, L., Wang, Z., Liu, S. S., . . . Cao, T. S. (2016). Effects of race and  
941 sex on cerebral hemodynamics, oxygen delivery and blood flow distribution in response  
942 to high altitude. *Scientific Reports*, 6, 30500. doi:10.1038/srep30500  
943 Mano, T., Iwase, S., & Toma, S. (2006). Microneurography as a tool in clinical neurophysiology  
944 to investigate peripheral neural traffic in humans. *Clinical Neurophysiology*, 117(11),  
945 2357-2384. doi:10.1016/j.clinph.2006.06.002  
946 Monge, C., Leon-Velarde, F., & Arregui, A. (1989). Increasing prevalence of excessive  
947 erythrocytosis with age among healthy high-altitude miners. *New England Journal of*  
948 *Medicine*, 321(18), 1271. doi:10.1056/nejm198911023211819  
949 Morgan, T. J. (2009). The Stewart approach--one clinician's perspective. *Clinical Biochemistry*  
950 *Reviews*, 30(2), 41-54.  
951 Orr, J. E., Heinrich, E. C., Djokic, M., Gilbertson, D., Deyoung, P. N., Anza-Ramirez, C., . . .  
952 Simonson, T. (2018). Adaptive Servoventilation as Treatment for Central Sleep Apnea  
953 Due to High-Altitude Periodic Breathing in Nonacclimatized Healthy Individuals. *High*  
954 *Altitude Medicine and Biology*, 19(2), 178-184. doi:10.1089/ham.2017.0147  
955 Pei, T., Li, X., Tao, F., Xu, H., You, H., Zhou, L., . . . Gao, Y. (2012). Burden of disease  
956 resulting from chronic mountain sickness among young Chinese male immigrants in  
957 Tibet. *BMC Public Health*, 12(1), 401. doi:10.1186/1471-2458-12-401  
958 Penalzoza, D., & Arias-Stella, J. (2007). The heart and pulmonary circulation at high altitudes:  
959 healthy highlanders and chronic mountain sickness. *Circulation*, 115(9), 1132-1146.  
960 doi:10.1161/circulationaha.106.624544  
961 Pillar, G., Berall, M., Berry, R., Etzioni, T., Shrater, N., Hwang, D., . . . Penzel, T. (2019).  
962 Detecting central sleep apnea in adult patients using WatchPAT-a multicenter validation  
963 study. *Sleep Breath*. doi:10.1007/s11325-019-01904-5  
964 Pleurdeau, D. (2005). Human Technical Behavior in the African Middle Stone Age: The Lithic  
965 Assemblage of Porc-Epic Cave (Dire Dawa, Ethiopia). *African Archaeological Review*,  
966 22(4), 177-197. doi:10.1007/s10437-006-9000-7  
967 Porcelli, S., Marzorati, M., Healey, B., Terraneo, L., Vezzoli, A., Bella, S. D., . . . Samaja, M.  
968 (2017). Lack of acclimatization to chronic hypoxia in humans in the Antarctica. *Scientific*  
969 *Reports*, 7(1), 18090. doi:10.1038/s41598-017-18212-1  
970 Rudski, L. G., Lai, W. W., Afilalo, J., Hua, L., Handschumacher, M. D., Chandrasekaran, K., . . .  
971 Schiller, N. B. (2010). Guidelines for the echocardiographic assessment of the right heart  
972 in adults: a report from the American Society of Echocardiography endorsed by the  
973 European Association of Echocardiography, a registered branch of the European Society  
974 of Cardiology, and the Canadian Society of Echocardiography. *Journal of the American*  
975 *Society of Echocardiography*, 23(7), 685-713; quiz 786-688.  
976 doi:10.1016/j.echo.2010.05.010  
977 Ryan, B. J., Wachsmuth, N. B., Schmidt, W. F., Byrnes, W. C., Julian, C. G., Lovering, A. T., . . .  
978 . Roach, R. C. (2014). AltitudeOmics: rapid hemoglobin mass alterations with early  
979 acclimatization to and de-acclimatization from 5260 m in healthy humans. *PLoS One*,  
980 9(10), e108788. doi:10.1371/journal.pone.0108788

- 981 Sahota, I. S., & Panwar, N. S. (2013). Prevalence of Chronic Mountain Sickness in high altitude  
982 districts of Himachal Pradesh. *Indian Journal of Occupational and Environmental*  
983 *Medicine*, 17(3), 94-100. doi:10.4103/0019-5278.130839
- 984 Samaja, M., Mariani, C., Prestini, A., & Cerretelli, P. (1997). Acid-base balance and O<sub>2</sub>  
985 transport at high altitude. *Acta Physiologica Scandinavica*, 159(3), 249-256.  
986 doi:10.1046/j.1365-201X.1997.574342000.x
- 987 Schmidt, W., & Prommer, N. (2005). The optimised CO-rebreathing method: a new tool to  
988 determine total haemoglobin mass routinely. *European Journal of Applied Physiology*,  
989 95(5-6), 486-495. doi:10.1007/s00421-005-0050-3
- 990 Severinghaus, J. W., Mitchell, R. A., Richardson, B. W., & Singer, M. M. (1963). Respiratory  
991 control at high altitude suggesting active transport regulation of csf ph. *Journal of*  
992 *Applied Physiology*, 18, 1155-1166. doi:10.1152/jappl.1963.18.6.1155
- 993 Sherpa, L. Y., Deji, Stigum, H., Chongsuvivatwong, V., Thelle, D. S., & Bjertness, E. (2010).  
994 Obesity in Tibetans aged 30-70 living at different altitudes under the north and south  
995 faces of Mt. Everest. *International journal of environmental research and public health*,  
996 7(4), 1670-1680. doi:10.3390/ijerph7041670
- 997 Siebenmann, C., Keiser, S., Robach, P., & Lundby, C. (2017). CORP: The assessment of total  
998 hemoglobin mass by carbon monoxide rebreathing. *Journal of Applied Physiology*  
999 (1985), 123(3), 645-654. doi:10.1152/japplphysiol.00185.2017
- 1000 Simpson, L. L., Busch, S. A., Oliver, S. J., Ainslie, P. N., Stembridge, M., Steinback, C. D., &  
1001 Moore, J. P. (2019). Baroreflex control of sympathetic vasomotor activity and resting  
1002 arterial pressure at high altitude: insight from Lowlanders and Sherpa. *Journal of*  
1003 *Physiology*, 597(9), 2379-2390. doi:10.1113/jp277663
- 1004 Smith, K. J., MacLeod, D., Willie, C. K., Lewis, N. C., Hoiland, R. L., Ikeda, K., . . . Ainslie, P.  
1005 N. (2014). Influence of high altitude on cerebral blood flow and fuel utilization during  
1006 exercise and recovery. *Journal of Physiology*, 592(24), 5507-5527.  
1007 doi:10.1113/jphysiol.2014.281212
- 1008 Stembridge, M., Ainslie, P. N., Boulet, L. M., Anholm, J., Subedi, P., Tymko, M. M., . . . Shave,  
1009 R. (2019). The independent effects of hypovolaemia and pulmonary vasoconstriction on  
1010 ventricular function and exercise capacity during acclimatisation to 3800 m. *Journal of*  
1011 *Physiology*, 597(4), 1059-1072. doi:10.1113/jp275278
- 1012 Swenson, E. R. (2012). Normal exercise capacity in chronic mountain sickness: how high can the  
1013 hematocrit go without consequence? *Chest*, 142(4), 823-825. doi:10.1378/chest.12-0933
- 1014 Thomas, K. N., Lewis, N. C., Hill, B. G., & Ainslie, P. N. (2015). Technical recommendations  
1015 for the use of carotid duplex ultrasound for the assessment of extracranial blood flow.  
1016 *American journal of physiology. Regulatory, integrative and comparative*  
1017 *physiology*309(7), R707-720. doi:10.1152/ajpregu.00211.2015
- 1018 Tremblay, J. C., Hoiland, R. L., Carter, H. H., Howe, C. A., Stembridge, M., Willie, C. K., . . .  
1019 Ainslie, P. N. (2018). UBC-Nepal expedition: upper and lower limb conduit artery shear  
1020 stress and flow-mediated dilation on ascent to 5,050 m in lowlanders and Sherpa.  
1021 *American journal of physiology. Heart and circulatory physiology*, 315(6), H1532-  
1022 h1543. doi:10.1152/ajpheart.00345.2018
- 1023 Tremblay, J. C., Howe, C. A., Ainslie, P. N., & Pyke, K. E. (2018). UBC-Nepal Expedition:  
1024 imposed oscillatory shear stress does not further attenuate flow-mediated dilation during  
1025 acute and sustained hypoxia. *American journal of physiology. Heart and circulatory*  
1026 *physiology*, 315(1), H122-h131. doi:10.1152/ajpheart.00717.2017

1027 Tremblay, J. C., Thom, S. R., Yang, M., & Ainslie, P. N. (2017). Oscillatory shear stress, flow-  
1028 mediated dilatation, and circulating microparticles at sea level and high altitude.  
1029 *Atherosclerosis*, 256, 115-122. doi:10.1016/j.atherosclerosis.2016.12.004

1030 Tymko, M. M., Ainslie, P. N., MacLeod, D. B., Willie, C. K., & Foster, G. E. (2015). End tidal-  
1031 to-arterial CO<sub>2</sub> and O<sub>2</sub> gas gradients at low- and high-altitude during dynamic end-tidal  
1032 forcing. *American journal of physiology. Regulatory, integrative and comparative*  
1033 *physiology*, 308(11), R895-906. doi:10.1152/ajpregu.00425.2014

1034 Tymko, M. M., Hoiland, R. L., Kuca, T., Boulet, L. M., Tremblay, J. C., Pinske, B. K., . . .  
1035 Foster, G. E. (2016). Measuring the human ventilatory and cerebral blood flow response  
1036 to CO<sub>2</sub>: a technical consideration for the end-tidal-to-arterial gas gradient. *Journal of*  
1037 *Applied Physiology (1985)*, 120(2), 282-296. doi:10.1152/jappphysiol.00787.2015

1038 Tymko, M. M., Tremblay, J. C., Hansen, A. B., Howe, C. A., Willie, C. K., Stenbridge, M., . . .  
1039 Ainslie, P. N. (2017). The effect of alpha<sub>1</sub> -adrenergic blockade on post-exercise brachial  
1040 artery flow-mediated dilatation at sea level and high altitude. *Journal of Physiology*,  
1041 595(5), 1671-1686. doi:10.1113/jp273183

1042 Villafuerte, F. C., & Corante, N. (2016). Chronic Mountain Sickness: Clinical Aspects, Etiology,  
1043 Management, and Treatment. *High Altitude Medicine and Biology*, 17(2), 61-69.  
1044 doi:10.1089/ham.2016.0031

1045 Wang, X., Wei, W., Yuan, F., Li, S., Lin, J., & Zhang, J. (2018). Regional cerebral blood flow in  
1046 natives at high altitude: An arterial spin labeled MRI study. *Journal of Magnetic*  
1047 *Resonance Imaging*. doi:10.1002/jmri.25996

1048 Wehrlin, J. P., & Hallen, J. (2006). Linear decrease in .VO<sub>2</sub>max and performance with  
1049 increasing altitude in endurance athletes. *European Journal of Applied Physiology*, 96(4),  
1050 404-412. doi:10.1007/s00421-005-0081-9

1051 Willie, C. K., Colino, F. L., Bailey, D. M., Tzeng, Y. C., Binsted, G., Jones, L. W., . . . Ainslie,  
1052 P. N. (2011). Utility of transcranial Doppler ultrasound for the integrative assessment of  
1053 cerebrovascular function. *Journal of Neuroscience Methods*, 196(2), 221-237.  
1054 doi:10.1016/j.jneumeth.2011.01.011

1055 Willie, C. K., Smith, K. J., Day, T. A., Ray, L. A., Lewis, N. C., Bakker, A., . . . Ainslie, P. N.  
1056 (2014). Regional cerebral blood flow in humans at high altitude: gradual ascent and 2 wk  
1057 at 5,050 m. *Journal of Applied Physiology (1985)*, 116(7), 905-910.  
1058 doi:10.1152/jappphysiol.00594.2013

1059 Willie, C. K., Stenbridge, M., Hoiland, R. L., Tymko, M. M., Tremblay, J. C., Patrician, A., . . .  
1060 Ainslie, P. N. (2018). UBC-Nepal Expedition: An experimental overview of the 2016  
1061 University of British Columbia Scientific Expedition to Nepal Himalaya. *PLoS One*,  
1062 13(10), e0204660. doi:10.1371/journal.pone.0204660

1063 Woolcott, O. O., Gutierrez, C., Castillo, O. A., Elashoff, R. M., Stefanovski, D., & Bergman, R.  
1064 N. (2016). Inverse association between altitude and obesity: A prevalence study among  
1065 andean and low-altitude adult individuals of Peru. *Obesity (Silver Spring)*, 24(4), 929-  
1066 937. doi:10.1002/oby.21401

1067 Yalamanjali, S., Farajian, V., Hamilton, C., Pott, T. R., Samuelson, C. G., & Friedman, M.  
1068 (2013). Diagnosis of obstructive sleep apnea by peripheral arterial tonometry: meta-  
1069 analysis. *JAMA Otolaryngology Head and Neck Surgery*, 139(12), 1343-1350.  
1070 doi:10.1001/jamaoto.2013.5338

1071 Zhang, X. L., Ha, B. B., Wang, S. J., Chen, Z. J., Ge, J. Y., Long, H., . . . Gao, X. (2018). The  
1072 earliest human occupation of the high-altitude Tibetan Plateau 40 thousand to 30  
1073 thousand years ago. *Science*, *362*(6418), 1049-1051. doi:10.1126/science.aat8824  
1074 Zhou, D., Udpa, N., Ronen, R., Stobdan, T., Liang, J., Appenzeller, O., . . . Haddad, G. G.  
1075 (2013). Whole-genome sequencing uncovers the genetic basis of chronic mountain  
1076 sickness in Andean highlanders. *American Journal of Human Genetics*, *93*(3), 452-462.  
1077 doi:10.1016/j.ajhg.2013.07.011

**Table 1: Overview of experimental studies**

<b>Study</b>	<b>Study Title</b>	<b>Study Aim</b>	<b>Participants</b>	<b>Techniques used</b>
1	The common carotid artery vasomotor response to the cold pressor test at sea level and high altitude in lowlanders and Andeans: the role of oxygen	To determine the effects of altitude on the common carotid artery vasomotor response to the cold pressor test at sea level and high altitude	Lowlanders (n =14); non-EE Andeans (n = 12)	Duplex ultrasound; finger photoplethysmography
2	Nitric oxide-mediated endothelium-dependent vasodilation in lowlanders at sea level and high altitude	To determine the influence of oxidative stress on endothelial dependent vasodilatory function in lowlanders with chronic exposure to high altitude.	Lowlanders (n =11)	Venous occlusion plethysmography with intra-brachial infusions of acetylcholine and sodium nitroprusside
3	Investigating the role of haemoglobin concentration, plasma volume and absolute blood volume on cardiac function and exercise capacity in high altitude natives	To explore whether hemoglobin mass or absolute blood volume is associated with exercise performance in the Andean population, and whether differences in performance are related to cardiac structure and function	Lowlanders (n =12); healthy Andeans (n = 40)	CO rebreathing; venous blood sampling; Duplex ultrasound; maximal exercise test
4	Sympathetic function in lowlanders and high altitude Andean's with and without EE	To investigate sympathetic nervous activity in Peruvian highlanders and identify a specific link between sympathetic hyperactivity and elevated pulmonary arterial pressure	Lowlanders (n =18); non-EE Andeans (n = 10); Andeans with EE (n=10)	Microneurography to assess muscle sympathetic nervous activity; Duplex ultrasound; finger photoplethysmography
5	The effects of oxidative stress on cutaneous vasodilation at sea level and high altitude	To determine the role of oxidative stress on cutaneous vascular function at sea level and high altitude	Lowlanders (n =11); non-EE Andeans (n = 11)	Microdialysis; laser-Doppler flowmetry
6	The effects of venesection on peripheral and central vascular function in Andeans	To quantify the influence of reductions in hematocrit (via blood removal) on central and peripheral vascular function	Andeans with EE (n=10)	Duplex ultrasound; arterial/venous blood sampling; finger



7	with EE The factors effecting resting and active (exercising) skeletal muscle blood flow through the process of acclimatization, adaptation and maladaptation to high altitude	in Andean highlanders suffering from EE To provide a integrative assessment of the factors influencing skeletal muscle blood flow during adaptation and maladaptation to high altitude	Lowlanders (n =11); non-EE Andeans (n = 10); Andeans with EE (n = 8)	photoplethysmography Exercise tests; Microneurography to assess muscle sympathetic nervous activity; Brachial catheterization; Duplex ultrasound; local arterial pharmacological infusions Duplex ultrasound
8	Pulmonary vascular changes to acute and chronic high altitude hypoxia	To study pulmonary vascular responses at rest and during exercise, at both low and high altitude in lowlanders and in Andeans with and without EE	Lowlanders (n =11); non-EE Andeans (n = 13); Andeans with EE (n = 9)	Duplex ultrasound
9	Endothelial function and shear stress in high altitude Andeans with and without EE	To characterize resting shear stress patterns and assess endothelial function via flow-mediated dilation in response to transient and sustained elevations in shear stress	Non-EE Andeans (n = 33); Andeans with EE (n = 20)	Duplex ultrasound; handgrip exercise
10	The global cerebral blood flow and intracranial pressure response to hypobaric hypoxia in high-altitude Andeans with and without EE	To determine the effects of high altitude on cerebral blood flow and intracranial pressure in high-altitude Andeans with and without EE	Non-EE Andeans (n = 33); Andeans with EE (n = 20)	Duplex ultrasound
11	The effects of iron supplementation on vascular function between lowlanders and high altitude Andeans	To determine the effect of iron sucrose intravenous supplementation on peripheral vascular function between healthy lowlanders and Andean highlanders	Lowlanders (n = 24); non-EE Andeans (n = 24)	Duplex ultrasound; venous blood sampling;
12	The effect of a positive expiratory pressure mask with dead space on sleep, acute mountain sickness and cognitive function during	To assess the combined effect of positive expiratory pressure and dead space on sleep, acute mountain sickness and cognitive function during normobaric and hypobaric hypoxia.	Lowlanders (n = 15)	Sleep monitoring

	normobaric and hypobaric hypoxia			
13	Redox-regulation of cerebrovascular function during acute exposure to environmental hypoxia	To examine to what extent free radical-mediated alterations in nitric oxide bioavailability contribute towards systemic vascular impairment following acute exposure to environmental hypoxia and to what extent this translates to the cerebrovasculature and corresponding implications for cognition.	Lowlanders (n = 12); non-EE Andeans (n = 18)	Duplex ultrasound; Transcranial Doppler ultrasound; finger photoplethysmography; venous blood sampling; electron paramagnetic resonance spectroscopy; ozone chemiluminescence; hs-ELISA; fluorimetry; HPLC; neurovascular coupling; cognition
14	The effect of high altitude exposure on the regulation of cerebral blood flow during heat and cold stress	To understand how high-altitude acclimatization impacts the regulation of cerebral blood flow during heat and cold challenges.	Lowlanders (n =11)	Duplex ultrasound; esophageal and rectal temperature monitoring; arterial blood sampling;
15	Renal reactivity at high altitude	To determine the effects of acute and chronic altitude exposure on kidney function in lowlanders and Andean highlanders	Lowlanders (n = 30); non-EE Andeans (n = 17); Andeans with EE (n = 11)	Duplex ultrasound; urine sampling;

*Definition of abbreviations:* EE, excessive erythrocytosis. Each of these investigations had distinct outcome measurements, and data were not pooled across individual studies.

1 **Table 2: Participant demographics in Peru**

2

	<b>Lowlanders</b>	<b>Males EE-</b>	<b>Males EE+</b>	<b>Females EE-</b>
n	30 (3F)	35	22	10
Age (yrs)	29.9 ± 7.8	30.2 ± 11.2	44.1 ± 12.8*	25.5 ± 3.1
Stature (cm)	175.3 ± 5.8	162.6 ± 4.4	159.8 ± 5.8	152.1 ± 5.0
Mass (Kg)	72.5 ± 7.9	63.8 ± 8.1	66.7 ± 9.9	53.6 ± 4.1
BMI (Kg/m <sup>2</sup> )	23.5 ± 1.6	24.2 ± 3.2	26.1 ± 3.3	23.2 ± 2.1

3 *Definition of abbreviations:* yrs, years; cm, centimeter; kg, kilogram; m, meter; EE+, Andeans  
 4 with excessive erythrocytosis; EE-, Andeans without excessive erythrocytosis. \*P<0.05, Males  
 5 EE- vs EE+.

6

7

8 **Table 3: Arterial Blood Data**

9

	<b>Male LL (344m)</b>	<b>Male LL Day 14 (4300m)</b>	<b>Male Andean EE+ (4300m)</b>	<b>Male Andean EE- (4300m)</b>
n	13	13	16	16
pH	7.42 ± 0.02	7.47 ± 0.03*	7.42 ± 0.02†	7.45 ± 0.03‡
PaCO <sub>2</sub> (mmHg)	40.8 ± 2.1	28.6 ± 1.5*	35.0 ± 3.2†	29.2 ± 3.6‡ <sup>l</sup>
PaO <sub>2</sub> (mmHg)	98.7 ± 7.4	50.2 ± 5.6*	44.2 ± 3.7†	49.42 ± 7.1
HCO <sub>3</sub> (mmol/l)	26.2 ± 1.5	20.7 ± 1.3*	22.5 ± 1.5†	20.0 ± 2.0‡
SaO <sub>2</sub> (%)	97.8 ± 0.7	87.8 ± 2.6*	79.0 ± 4.7†	86.4 ± 4.0‡

10 *Definition of abbreviations:* mmHg, millimeters of mercury, mmol, millimoles; l, liters; EE+,  
 11 Andeans with excessive erythrocytosis; EE-, Andeans without excessive erythrocytosis. LL, low-  
 12 landers. \*P<0.05, low-landers sea level vs low-landers Day 14. †P<0.05, vs low-landers Day 14.  
 13 ‡EE+ vs EE-.

14

15 **Table 4: Venous Blood**  
 16

	<b>Male LL (344m)</b>	<b>Male LL Day 14 (4300m)</b>	<b>Male Andean EE+ (4300m)</b>	<b>Male Andean EE- (4300m)</b>	<b>Female Andean (4300m)</b>
n	24	17	21	26	11
Hb (g/dl)	14.9 ± 1.0	17.4 ± 1.7*	22.6 ± 1.7†‡	18.5 ± 1.7†	16.8 ± 1.3†
Blood viscosity (cP)	4.3 ± 0.7	4.9 ± 0.6*	8.5 ± 1.2†‡	6.0 ± 0.8†	4.9 ± 0.7†

17 *Definition of abbreviations:* g, grams; l, liters; EE+, Andeans with excessive erythrocytosis; EE-,  
 18 Andeans without excessive erythrocytosis. LL, low-landers. \*P<0.05, low-landers sea level vs  
 19 low-landers Day 14. †P<0.05, vs low-landers Day 14. ‡P<0.05, male EE+ vs male EE-.  
 20 †P<0.05, male EE- vs female EE-.  
 21

22 **Figure Legends**

23

24 **Figure 1.** A timeline of Global REACH's latest research expedition to Peru, and a schematic of  
25 the laboratory facility used in Cerro de Pasco.

26

27 **Figure 2.** Davenport diagram illustrating acid-base balance between male lowlanders at sea level  
28 (●), male lowlanders after 14 days at 4300m (◆), Andean highlanders diagnosed with EE at  
29 4300m (▲), Andean highlanders without EE at 4300m (■). *Definition of abbreviations:* EE,  
30 excessive erythrocytosis;  $\text{HCO}_3^-$ , bicarbonate;  $\text{PaCO}_2$ , partial pressure of arterial carbon dioxide.

31

32 **Figure 3.** Exercise performance between male lowlanders and Andean highlanders. Panel A, box  
33 and whisker plot for relative  $\text{VO}_2$  max (ml/kg/min). Panel B, box and whisker plot for peak  
34 wattage obtained during the exercise test. *Definition of abbreviations:* EE, excessive  
35 erythrocytosis; F, female; HA, high altitude; kg, kilograms; LL, lowlanders; M, male; min,  
36 minutes; ml, milliliters; SL, sea level. Brackets represent differences between data sets ( $P < 0.05$ ).

37

38

39

5000

Studies conducted between June 28<sup>th</sup> – July 22<sup>nd</sup>

4000

Ascent from Lima on June 26<sup>th</sup> - 28<sup>th</sup>

3000

2000


1000

0

Lima  
June 25<sup>th</sup>

Lima

Cerro de Pasco



**Floor Plan**

- |                       |                              |
|-----------------------|------------------------------|
| 1. Testing laboratory | 7. Residential room          |
| 2. Pre screening room | 8. Kitchen/ dining area      |
| 3. Testing laboratory | 9. Blood analysis laboratory |
| 4. Testing laboratory | 10. Participant waiting area |
| 5. Storage room       | 11. Testing laboratory       |
| 6. Storage room       | 12. Testing laboratory       |
|                       | *. Bathrooms                 |

Return to Lima on July 22<sup>nd</sup> and 23<sup>rd</sup>

Time (days)

